Official Protocol Title:  
NCT number:  [STUDY_ID_REMOVED] 
Document Date:  05-Jul-2018A Phase 4 Randomized, Active-Comparator Controlled Trial to 
Study the Efficacy and Safety of Sugammadex (MK-8616) for the 
Reversal of Neuromuscular Blockade Induced by [CONTACT_721950]:   MK - 8616 1
Protocol/Amendment No.: 146-01 
MK-8616-146-01 Final Protocol 5-Jul- 2018
ConfidentialTHIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., 
WHITEHOUSE STATION , NJ, U.S.A.
SPONSOR:
[COMPANY_006] Sharp & Dohme Corp., a subsidiary  of [COMPANY_006] & Co., Inc. 
(hereafter referred to as the Sponsor or [COMPANY_006])
One [COMPANY_006] Drive
P.O. Box [ADDRESS_985968] 
information can be found in the Investigator Trial File 
Binder (or equivalent) .
TITLE:
A Phase 4 Randomized, Active -Comparator Controlled Trial to Study  the Efficacy  and 
Safety  of Sugammadex (MK -8616) for the Reversal of Neuromuscular Blockade Induced by 
[CONTACT_721951]:   68,[ADDRESS_985969] NUMBER:   2017-000188-[ADDRESS_985970]:   MK-8616 2
Protocol/Amendment No.: 146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
ConfidentialTABLE OF CONTENTS
SUMMARY OF CHANGES .................................................................................................. 9
1.0 TRIAL SUMMARY .................................................................................................. 17
2.0 TRIAL DESIGN ........................................................................................................ 18
Trial Design ........................................................................................................... 18 2.1
Trial Diagram ........................................................................................................ 21 2.2
3.0 OBJECTIVE(S) & HYPOTHESIS(ES) .................................................................. 22
Primary Objective(s) & Hypothesis(es) .............................................................. 22 3.1
Secondary Objective(s) & Hypothesis(es) ........................................................... 22 3.2
Exploratory Objectives ......................................................................................... 23 3.3
4.0 BACKGROUND & RATIONALE .......................................................................... [ADDRESS_985971] Population .................................... 24 4.2.1
Rationale for Dose Selection/Regimen ............................................................... 25 4.2.2
Rationale for the Use of Comparator ........................................................... 26 [IP_ADDRESS]
Rationale for Endpoints ...................................................................................... 26 4.2.3
Efficacy  Endpoints ....................................................................................... 26 [IP_ADDRESS]
Safety  Endpoints .......................................................................................... 26 [IP_ADDRESS]
Pharmacokinetic Endpoints ......................................................................... 28 [IP_ADDRESS]
Future Biomedical Research ........................................................................ 28 [IP_ADDRESS]
Benefit/Risk ........................................................................................................... 28 4.3
5.0 METHODOLOGY ................................................................................................... 29
Entry Criteria ........................................................................................................ 29 5.1
Diagnosis/Condition for Entry  into the Trial ...................................................... [ADDRESS_985972] Exclusion Criteria .................................................................................. 30 5.1.3
Trial Treatment(s) ................................................................................................ 32 5.2
Dose Selection .................................................................................................... 32 5.2.1
Dose Selection (Preparation) ....................................................................... 32 [IP_ADDRESS] 
  04YY9X 
  05C8LJ
Product:   MK-8616 3
Protocol/Amendment No.: 146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
ConfidentialTiming of Dose Administration .......................................................................... 33 5.2.2
Trial Blinding...................................................................................................... 33 5.2.3
Randomization or Treatment Allocation ............................................................ 35 5.3
Stratification .......................................................................................................... 35 5.4
Concomitant Medications/Vaccinations (Allowed & Prohibited) .................... 35 5.5
Rescue Medications & Supportive Care ............................................................. 36 5.6
Diet/Activity/Other Considerations ..................................................................... [ADDRESS_985973] Replacement Strategy ............................................................................. 36 5.9
Beginning and End of the Trial ........................................................................... 36 5.10
Clinical Criteria for Early Trial Termination ................................................... 36 5.11
6.0 TRIAL FLOW CHART ........................................................................................... 37
7.0 TRIAL PROCEDURES ........................................................................................... 40
Trial Procedures ................................................................................................... 40 7.1
Administrative Procedures .................................................................................. 40 7.1.1
Informed Consent ......................................................................................... 40 [IP_ADDRESS]
[IP_ADDRESS].1 General Informed Consent .................................................................... 40
[IP_ADDRESS].2 Consent and Collection of Specimens for Future Biomedical 
Research ................................................................................................ 41
Inclusion/Exclusion Criteria ........................................................................ 41 [IP_ADDRESS]
Subject I dentification Card .......................................................................... 41 [IP_ADDRESS]
Medical History ........................................................................................... 41 [IP_ADDRESS]
Prior and Concomitant Medications Review ............................................... 41 [IP_ADDRESS]
[IP_ADDRESS].1 Prior Medications .................................................................................. 41
7.1.1 .5.2 Concomitant Medications ..................................................................... 41
Assignment of Screening Number ............................................................... 42 [IP_ADDRESS]
Assignment of Treatment/Randomization Number ..................................... 42 [IP_ADDRESS]
Trial Compliance (Medication) .................................................................... 42 [IP_ADDRESS]
Clinical Procedures/Assessments ........................................................................ 42 7.1.2
Physical Examination ................................................................................... 42 [IP_ADDRESS]
BodyWeight and Height ............................................................................. 43 [IP_ADDRESS]
Body Mass Index ......................................................................................... 43 [IP_ADDRESS] 
  04YY9X 
  05C8LJ
Product:   MK-8616 4
Protocol/Amendment No.: 146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
ConfidentialElectrocardiogram ........................................................................................ 43 [IP_ADDRESS]
Vital Signs.................................................................................................... 43 [IP_ADDRESS]
Administration of Neuromuscular Blocking Agents ................................... 45 [IP_ADDRESS]
Neuromuscular Monitoring .......................................................................... 45 [IP_ADDRESS]
Laboratory  Procedures/Assessments .................................................................. 45 7.1.3
Laboratory  Safet y Evaluations (Hematology and Chemistry) ..................... 46 [IP_ADDRESS]
Pregnancy  Tests ........................................................................................... 47 [IP_ADDRESS]
Pharmacokinetic Evaluations ....................................................................... 47 [IP_ADDRESS]
[IP_ADDRESS].1 Blood Collection for Plasma MK -8616 ................................................ 47
Future Biomedical Research Samples ......................................................... 47 [IP_ADDRESS]
Other Procedures ................................................................................................ .48 7.1.4
Withdrawal/Discontinuation ........................................................................ 48 [IP_ADDRESS]
[IP_ADDRESS].1 Withdrawal From Future Biomedical Research ................................... 48
[IP_ADDRESS].[ADDRESS_985974] to Follow -up.................................................................................. 48
[IP_ADDRESS].[ADDRESS_985975] Blinding/Unblinding ................................................................ 49
Calibration of Equipment ............................................................................. 49 [IP_ADDRESS]
Visit Requirements .............................................................................................. 49 7.1.5
Screening (V1) ............................................................................................. 49 [IP_ADDRESS]
Peri-anesthetic Visit (V2) ............................................................................ 50 [IP_ADDRESS]
Post-Anesthetic Visit (V3)........................................................................... 53 [IP_ADDRESS]
Follow -up Safet y Contact (V4) .................................................................... 53 [IP_ADDRESS]
Assessing and Recording Adverse Events and Patient/Device Events ............. 53 7.2
Definition of an Overdose for This Protocol and Reporting of Overdose to 7.2.1
the Sponsor .......................................................................................................... 55
Reporting of Pregnancy  and Lactation to the Sponsor ....................................... 55 7.2.2
Immediate Reporting of Adverse Events and Incidents to the Sponsor ............. 56 7.2.3
Serious Adverse Events and Incidents ......................................................... 56 [IP_ADDRESS]
Events of Clinical I nterest ............................................................................ 57 [IP_ADDRESS]
Evaluating Adverse Events ................................................................................. 58 7.2.4
Sponsor Responsibility  for Reporting Adverse Events and Patient/Device 7.2.[ADDRESS_985976]:   MK-8616 5
Protocol/Amendment No.: 146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
ConfidentialClinical Adjudication Committee ....................................................................... 61 7.3.2
Neuromuscular Monitoring Adjudication Committee ................................ .61 [IP_ADDRESS]
8.0 STATISTICAL ANALYSIS PLAN ........................................................................ 62
Statistical Analysis Plan Summary ..................................................................... 62 8.1
Responsibility for Analyses/In -House Blinding ................................................. 63 8.2
Hypotheses/Estimation ......................................................................................... 63 8.3
Analysis Endpoints ............................................................................................... 63 8.4
Efficacy  Endpoints .............................................................................................. 64 8.4.1
Safety  Endpoints ................................................................................................ .64 8.4.2
Pharmacokinetic Endpoints ................................................................................ 65 8.4.3
Derivations of Efficacy  /Pharmacokinetics Endpoints ....................................... 66 8.4.4
Analysis Populations ............................................................................................. 67 8.5
Efficacy  Anal ysis Population .............................................................................. 67 8.5.1
Safety Anal ysis Population ................................................................................. 67 8.5.2
Pharmacokinetic Population ............................................................................... 67 8.5.3
Statistical Methods ................................................................................................ 68 8.6
Statistical Methods for Efficacy  Anal yses.......................................................... 68 8.6.1
Statistical Methods for Safety Anal yses............................................................. 69 8.6.2
Statistical Methods for Pharmacokinetic Anal ysis............................................. 71 8.6.3
Summaries of Baseline Characteristics, Demographics, and Other Anal yses....72 8.6.4
Demographic and Baseline Characteristics ................................................. 72 [IP_ADDRESS]
Population PK Analy ses.............................................................................. 72 [IP_ADDRESS]
Interim Analyses ................................................................................................... 73 8.7
Multiplicity ............................................................................................................ 73 8.8
Sample Size and Power ......................................................................................... 73 8.9
Sample Size and Power for Efficacy  Analy ses................................................... 73 8.9.1
Sample Size for Safety  Analy ses........................................................................ 75 8.9.2
Precision Estimates for Pharmacokinetic Parameters (AUC0 -inf, Cmax) ......... [ADDRESS_985977] of Baseline Factors ........................................... 76 8.10
Compliance (Medication Adherence) .................................................................. [ADDRESS_985978]:   MK-8616 6
Protocol/Amendment No.: 146-[ADDRESS_985979]/Destruction/Returns and Reconciliation .............................................. [ADDRESS_985980] Records ..................................................................... 79 10.1.2
Confidentiality  of Investigator Information ........................................................ 79 10.1.3
Confidentiality  of IRB/IEC I nformation ............................................................. [ADDRESS_985981] for Clinical Trials ........................................................ 85 12.1
Collection and Management of Specimens for Future Biomedical 12.2
Research ................................................................................................................. 87
Approximate Blood/Tissue Volumes Drawn/Collected by [CONTACT_75316] 12.[ADDRESS_985982] of Abbreviations and Definitions of Terms ................................................. 92 12.4
13.0 SIGNATURES ........................................................................................................... 94
Sponsor's Representative ..................................................................................... [ADDRESS_985983]:   MK - 8616 7
Protocol/Amendment No.: 146-[ADDRESS_985984] OF TABLES
Table 1 Trial Treatment ....................................................................................................... 32
Table 2 Vital Sign Measurements ........................................................................................ 44
Table 3 Laboratory  Tests ..................................................................................................... 46
Table 4 Evaluating Adverse Events ..................................................................................... 59
Table 5 Analy sis Strategy  for Key  Efficacy  Variables ........................................................ 69
Table 6 Analy sis Strategy
 for Safety  Parameters ................................................................ 71
Table 7 Sample Size for I nterim Analy
sis.......................................................................... 73
Table 8 Simulated power levels for the primary  comparison and related subgroup 
analyses as a function of sample size ..................................................................... 74
Table 9 Estimate of Incidence of Treatment Emergent Sinus Brad ycardia/Tach ycardia 
and 95% Upper Confidence Bound Based on Hypothetical Number of 
Subjects with Any Treatment Emergent Arrhy thmia Among 20 Subjects in a 
Treatment Group .................................................................................................... 75
Table 10 Differences in Incidence in Any Treatment Emergent Arrh ythmia between the 
Sugammadex and Neostigmine Groups Assuming Two-Sided 5% alpha level 
with [ADDRESS_985985]:   MK - 8616 8
Protocol/Amendment No.: 146-[ADDRESS_985986]:   MK - 8616 9
Protocol/Amendment No.: 146-01 
MK-8616-146-01 Final Protocol 5-Jul- 2018
ConfidentialSUMMARY OF CHANGES
PRIMARY REASON FOR THIS AMENDMENT:
Section 
Number (s)Section Title (s) Description of Change (s) Rationale
6.0 Trial Flow Chart Update to Trial Flow Chart to allow 
Visit 1 and Visit 2 to occur on the 
same day .To provide flexibility  to trial sites. 
ADDITIONAL CHANGE (S)FOR THIS AMENDMENT:
Section 
Number (s)Section Title (s) Description of Change (s) Rationale
2.1 Trial Design Added:
“The screening and peri-anesthetic 
visits may  occur on the same day  (see 
Section [IP_ADDRESS]).”Text added for consistency  with updates to 
the Trial Flow Chart and Section [IP_ADDRESS].
2.1 Trial Design Added: Formula for calculation of 
Ideal Bod y Weight (IBW)Clarification
2.1
4.2.3.2Trial Design
Safety  EndpointsAdded additional formatting and 
minor textual clarifications for safet y 
endpoints: treatment emergent sinus 
bradycardia, treatment emergent 
sinus tachy cardia, and other treatment 
emergent cardiac arrh ythmias
Added: Definition of baseline heart 
rate Additional text, formatting and definition of 
baseline heart rate added for clarityand 
alignment with Section 8.4.2 Safety 
Endpoints.
Note: the definition of these safety  endpoints 
has notchanged. 
  04YY9X 
  05C8LJ
Product:   MK - 8616 10
Protocol/Amendment No.: 146-01 
MK-8616-146-01 Final Protocol 5-Jul- 2018
ConfidentialSection 
Number (s)Section Title (s) Description of Change (s) Rationale
2.2 Trial Diagram Dose units for neostigmine corrected 
from 50 µ/kg to 50 µg/kgCorrection to dose units in Figure
.
2.2
6.0Trial Diagram
Trial Flow ChartScreening Visit (V1) window 
extended to 21 day sScreening Visit (V1) window extended from 
14 to 21 days to allow greater flexibility  for 
trial sites.
2.2
6.0Trial Diagram
Trial Flow ChartVisit 4: Follow -Up Visit/Phone Call 
occur s [ADDRESS_985987] study  medication 
administrationClarification provided for the timing of 
follow up visit/call .
5.1.[ADDRESS_985988] Exclusion Criteria Added note to exclusion criteria #5:
If dialysis or severe renal 
insufficiency  is not known or 
confirmed in the subject’s medical 
history , a creatinine clearance value 
should be calculated based upon the 
serum creatinine values obtained 
from local labs within the past 2 
weeks prior to 
Visit 1 or local labs 
performed between V1 and V2 (e.g., 
pre-operative testing).Additional clarification provided to assist 
trial sites with determining subject eligibility . 
  04YY9X 
  05C8LJ
Product:   MK - 8616 11
Protocol/Amendment No.: 146-01 
MK-8616-146-01 Final Protocol 5-Jul- 2018
ConfidentialSection 
Number (s)Section Title (s) Description of Change (s) Rationale
5.2.2 Timing of Dose 
AdministrationPrevious wording stated:  
Sugammadex or neostigmine 
administration should not exceed 20 
seconds.  
Updated for clarit y: 
The total duration of administration 
for all study  medication syringes 
(Dose 1 and Dose 2 syringe(s) as 
outlined in Study  Drug Manual) 
should not exceed a total of [ADDRESS_985989] the syringes containing 
sugammadex or neostigmine, should be 
administered within 20 seconds. The 
standardization of timing for study 
medication administration across treatment 
arms is necessary  to ensure consistency  of 
dosing across sites and to maintain the 
treatment blind .
5.2.3 Trial Blinding The 4thbulleted item regarding BSA 
responsibilities:
Be required to sign a statement for 
each subject (after V4 or 
discontinuation) confirming thatthe 
blind was maintained (treatment 
group, depth of block, drug 
preparation records , and TOF -
Watch SX®traces ).Textual update to provide consistency  with 
the BSA statement and other sections of the 
protocol and to clarify  the BSA signs this 
statement after Visit [ADDRESS_985990]:   MK - 8616 12
Protocol/Amendment No.: 146-01 
MK-8616-146-01 Final Protocol 5-Jul- 2018
ConfidentialSection 
Number (s)Section Title (s) Description of Change (s) Rationale
6.0
[IP_ADDRESS]
Appendix 12.3Trial Flow Chart
Pregnancy  Tests
Approximate Blood/Tissue 
Volumes Drawn/Collected 
by [CONTACT_721952] a serum β-human chorionic 
gonadotropin (β-hCG) pregnancy  test 
(results analyzed at a local lab) is
acceptable for Visit [ADDRESS_985991] of care process.
[IP_ADDRESS] Body Weight and Height The measurement of height and 
weight should be rounded to the 
nearest whole number.Clarification
[IP_ADDRESS] Electrocardiogram Added: Historical ECGs done prior to 
informed consent are not acceptable 
for the Visit [ADDRESS_985992] be performed prior 
to induction of anesthesia or prior to
administration of study medication.
Printing of the ECG trace is not 
required per protocol.Clarification provided for Visit 1 and Visit 2 
ECG requirements.
[IP_ADDRESS] Vital Signs Added: Table [ADDRESS_985993]:   MK - 8616 13
Protocol/Amendment No.: 146-01 
MK-8616-146-01 Final Protocol 5-Jul- 2018
ConfidentialSection 
Number (s)Section Title (s) Description of Change (s) Rationale
[IP_ADDRESS] Neuromuscular Monitoring Added additional text regarding the 
management of the study  subject if 
the TOF -Watch SX®data become 
unavailable due to a device 
malfunction.To provide additional guidance to sites on 
the protocol requirements for neuromuscular 
monitoring.
[IP_ADDRESS] Laboratory  S afety 
EvaluationsChanged:  “Safet y labs should be 
obtained pre-administration of study  
medication” to “Safet y labs should be 
obtained pre-administration of 
NMBA ”Correction
[IP_ADDRESS].[ADDRESS_985994] Blinding/ 
UnblindingUpdate:
Treatment/Vaccine identification 
information is to be unmasked ONLY 
if necessary  for the welfare of the 
subject.  Every effort should be made 
not to unblind the subject unless 
necessary .Removal of redundant text
[IP_ADDRESS] Calibration of Equipment Removed reference to list of critical 
equipment.Textual revisions were applied to clarify 
investigator responsibility  for calibration and 
maintenance of study  equipment.
[IP_ADDRESS] Peri-anesthetic Visit (V2) Added text to describe the conduct of 
protocol procedures when Visit 1 and 
Visit 2 occur on the same day . 
Section formatting updated (bullets 
and numbering).Additional guidance provided on the order of 
trial procedures in relation to randomiza tion 
in IRT, and new guidance for when Visit [ADDRESS_985995]:   MK - 8616 14
Protocol/Amendment No.: 146-01 
MK-8616-146-01 Final Protocol 5-Jul- 2018
ConfidentialSection 
Number (s)Section Title (s) Description of Change (s) Rationale
[IP_ADDRESS] Peri-anesthetic Visit (V2) Added: Refer to Section [IP_ADDRESS] 
Neuromuscular Monitoring for 
general guidance, in the event that 
TOF -Watch SX® data become 
unavailable due to device 
malfunction.To reference the additional guidance 
provided in Section [IP_ADDRESS] for managing 
subjects in the event of a TOF -Watch SX®
malfunction.
[IP_ADDRESS] Peri-anesthetic Visit (V2) Updated Item #8: Administration of 
anesthesia
Anesthesia will be induced and 
maintained according to the need of 
the subject.  Note:  All drugs, date of 
administration dosing time , and 
actual doses given to the subject will 
need to be recorded throughout the 
Peri-anesthetic visit and transferred to 
Sponsor database as required .The date of medication administration will be 
recorded in the Sponsor database (dosing 
time is not required) . 
However, investigator site personnel should 
follow site procedures with respect to 
documenting the date and time of 
medi cations administered during surgery .
[IP_ADDRESS] Peri-anesthetic Visit (V2) Items 5 and 6: The TOF -Watch SX®
accessories (transducers and
electrodes) and/or device can be 
affixed prior toadministration of
anesthesia or after induction of 
anesthesia butprior to administration 
ofNMBA.Clarification  
  04YY9X 
  05C8LJ
Product:   MK - 8616 15
Protocol/Amendment No.: 146-01 
MK-8616-146-01 Final Protocol 5-Jul- 2018
ConfidentialSection 
Number (s)Section Title (s) Description of Change (s) Rationale
7.2 Adverse Events Remove d:
“All device 
or patient events that 
occur after allocation/randomization 
must be reported by [CONTACT_721953], or are the 
result of a protocol -specified 
intervention, including but not 
limited to washout or discontinuation 
of usual therapy , diet, placebo 
treatment or a procedure .”Text was not applicable to the trial, the TOF -
Watch SX®device is only used after subject 
randomization. Device incident s can only be 
reported for randomized subjects in this trial.
[IP_ADDRESS] Serious Adverse Events 
and IncidentsRemoved:
“For the time period beginning at 
treatment allocation/randomization, 
any incident, including follow up to 
an incident, including death due to 
any cause, that occurs to any subject 
must be reported within [ADDRESS_985996] to 
be excluded from the trial, or is the 
result of a protocol -specified 
intervention, including but not 
limited to washout or discontinuation 
of usual therapy , diet, placebo 
treatment or a procedure.Text was not applicable to the trial, the TOF -
Watch SX®device is only used after subject 
randomization. Device incident s 
can only be 
reported for randomized subjects in this trial . 
  04YY9X 
  05C8LJ
Product:   MK - 8616 16
Protocol/Amendment No.: 146-01 
MK-8616-146-01 Final Protocol 5-Jul- 2018
ConfidentialSection 
Number (s)Section Title (s) Description of Change (s) Rationale
7.3.2 Clinical Adjudication 
Committee (CAC)Previous wording stated : “Upon 
identification of an eligible event, the 
Sponsor will query  the site to confirm 
that the event is eligible for 
adjudication based on the AE term 
and the timing of the event. ”
Revised to: Upon identification of 
such an event, the Sponsor may query 
the site for additional information.Removed language to be consistent with 
process; CAC will determine if an event is 
eligible for adjudication, not the site.
8.4.3 Pharmacokinetic E ndpoints Added heading for this section Correction: Section heading was added, as it 
was missing from the Table of Contents in 
the original protocol
Appendix 12.3 Approximate Blood/Tissue 
Volumes Drawn/Collected 
by [CONTACT_721954] 2 and Visit 3Assuming all parameters are collected, the 
minimum expected total blood volume 
collected:
At Visit 2 is 39.5 mL (45.5 mL 
maximum).
At Visit 3 is 15 mL  (23 mL  maximum)
Throughout 
protocolThroughout protocol Minor ty pographical updates For clarity 
  04YY9X 
  05C8LJ
Product:   MK - 8616 17
Protocol/Amendment No.: 146-[ADDRESS_985997] Identifiers MK-8616
Sugammadex
Trial Phase Phase 4
Clinical Indication Reversal of neuromuscular blockade
Trial Type Interventional
Type of control Active control without placebo
Route of administration Intravenous
Trial Blinding Double -blind
Treatment Groups Within each neuromuscular blocking agent (rocuronium or 
vecuronium ), the treatment groups are:
1)Moderate block and reversal with sugammadex 2 mg/kg , based on 
actual body weight ; or
2)Moderate block and reversal with sugammadex 2 mg/kg, based on 
ideal body w eight; or
3)Moderate block and reversal with Neostigmine 50 µg/kg up to 5 
mg maximum dose) + glycopyrrolate glycopyrrolate (10 µg/kg up 
to 1 mg maximu m dose) ; or
4)Deep block and reversal with sugammadex 4 mg/kg , based on 
actual body weight ; or
5)Deep block and reversal with sugammadex 4 mg/kg , based on 
ideal body w eight
Number of trial subjects Approx imately 200subjects will be enrolled.
Estimated duration of trial The Sponsor estimates that the trial will require approximately [ADDRESS_985998]’s last study -related phone call or visit.
Duration of Participation Each subject will participate in the trial for approximately 30days
from the time the subject signs the Informed Consent Form  through 
the final contact.  After a screening period , each subject will receiv e
anassigned treatment on their operative day.  After treatment , each 
subject will undergo a post-anesthetic visit a minimum of [ADDRESS_985999] of abbreviations used in this document can be found in Section 12. 4.Randomization Ratio 1:1:1:1:1 per neuromuscular blocking agent (NMBA) 
  04YY9X 
  05C8LJ
Product:   MK-8616 18
Protocol/Amendment No.: 146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
Confidential2.0TRIAL DESIGN
Trial Design 2.1
This is a randomized, active- comparator controlled, parallel -group, multi -site, double -blind , 
efficacy  and safet y trial of sugammadex for the reversal of neuromuscular blockade (NMB) 
induced by [CONTACT_721955] , where morbid 
obesity  is defined as body  mass index ≥ 40 kg/m2. The purpose of this study  is to evaluate the 
efficacy  of sugammadex when dosed according to actual body  weight (ABW) as compared 
with ideal body  weight (IBW) , with the latter tobe calculated based on the formula by 
[CONTACT_721956], 2015 [1].The formula for IBW is as follows:
•Males: 142 lb +3 lb/in over 63 inches (height) +1 lb/in over 71 inches (height) 
•Females: 119 lb +3 lb/in. over 60 inches (height) 
Height will be rounded to the nearest whole integer before appl ying the Kammerer formula.
The trial will consist of four visits: screening visit (V1) , peri-anesthetic visit (V2) , post-
anesthetic visit (V3), and a follow -upsafet ycontact (V4) .  The screening and peri-anesthetic 
visits may occur on the same day (see Section [IP_ADDRESS]) .  Subjects will be in the trial for 
approximately  [ADDRESS_986000] the NMBA for use as appropriate for the type of 
surgery , provided both the rocuronium andvecuronium strata remain open. S ubjects will be 
stratified b y NMBA b y anInteractive Voice Response S ystem(IVRS) to facilitate enrollment 
of the target number of randomized subjects into each stratum (appro ximately  30% of the 
overall planned sample size will be enrolled in the vecuronium stratum ).
Subjects will be randomized to depth of NMB (moderate or deep) and reversal agent 
(sugammadex or neostigmine + glycop yrrolate ). For each NMBA stratum (rocuronium or 
vecuronium), subjects will be randomize d to one of five treatment groups in a 1:1:1:1:1 ratio 
as follows: 
1.Moderate block and reversal with sugammadex 2mg/kg, based on ABW
2.Moderate block and reversal with sugammadex 2 mg/kg, based on IBW 
3.Moderate block and reversal with neostigmine (50 µg/kg up to 5mgmaximum dose) 
+ glycopyrrolatebased on ABW
4.Deep block and reversal with sugammadex 4 mg/kg, based on ABW 
5.Deep block and reversal with sugammadex 4 mg/kg , based on IBW  
  04YY9X 
  05C8LJ
Product:   MK - 8616 19
Protocol/Amendment No.: 146-01 
MK-8616-146-01 Final Protocol 5-Jul- 2018
ConfidentialSubjects should be maintained in either moderate or deep NMB intra-operatively , according 
to treatment assignment, until the time of reversal. Depth of block is to be assessed as 
described elsewhere via continuous neuromuscular transmission monitor ing (Section 
[IP_ADDRESS]). While fluctuations in depth of block are expected as matter of course to 
accommodate the needs of surgical procedures, additional doses of NMBA should be 
administered as clinically  necessary  for the duration of the surgery  in order fortarget 
mainte nance of the assigned depth of block as follows
:
Subjects randomized to moderate block are to be maintained in moderate block until 
the time of reversal. Either sugammadex 2 mg/kg or neostigmine (50 µg/kg up to 5mg 
maximum dose) + glycopyrrolate will be given after the last dose of administered 
NMBA and within 2minutes ofdetection of reappearance of second twitch ( T2) with 
a lower limit of train of four ( TOF )count 1 an
d upper limit of TOF count of 4.
Subjects randomized to deep block are to be maintained in deep block until the time 
of reversal. Sugammadex 4 mg/kg will be given after the last dose of administered 
NMBA andwithin 2minutes ofdetection of 1-[ADDRESS_986001]-tetanic counts (PTC)with a 
range of 1 -5 PTC anda TOF count of 0
.
Safet y endpoints include the incidence of treatment emergent sinus brady cardia, treatment 
emergent sinus tachycardia, or other treatment emergent cardiac arrhythmias after 
administration of sugammadex or neostigmine .  For the purpose of this study : 
Treatment e mergent sinus bradycardia is defined as meeting allof the following:
oa heart rate <60 bpm 
oa heart rate decrease dmore than 20% compared to the subject’s baseline 
heart rate value
ois sustained for at least 1 minute after administration of study  medication .
Treatment emergent sinus tachycardia is defined as 
meeting all of the following:
oa heart rate >100 bpm
oa heart rate increase dmore than 20% compared to the subject’s baseline heart 
rate value
ois sustained for at least 1 minute after administration of study  medication.
Other treatment emergent cardiac arrhythmias are defined asmeeting allof the 
following:
onew or worsening arrhy thmias (e.g., atrial fibrillation, atrial tachy cardia, 
ventricular fibrillation, or ventricular tach ycardia )
ois sustained for at least 1 minute after administration of study  medication.
*Baseline heart rate is defined as the heart rate taken after the last dose of NMBA is 
administered and (approximately  5 minutes) prior to administration of study medication.  
  04YY9X 
  05C8LJ
Product:   MK - 8616 20
Protocol/Amendment No.: 146-01 
MK-8616-146-01 Final Protocol 5-Jul- 2018
ConfidentialSafety  assessments, including AEs, serious adverse events (SAEs), and events of clinical 
interest (ECIs), will be recorded during the trial as noted in the Trial Flow Chart inSection 
6.0. Any perioperative events that occur in the operating room (OR)or post-anesthesia care 
(PACU )will be recorded by  [CONTACT_721957]. 
To ensure timel y reporting and comprehensive data collection ,the following types of events 
are prespecified as ECIs:
Clinically  relevant arrhythmias, inclusive of brady cardiaand tachycardia, defined as 
events necessitating intervention, as determined by [CONTACT_134970]. 
Hypersensitivity  and/or anaphy laxis
oPotential cases of hypersensitivity  and/or anaphy laxis will be adjudicated by [CONTACT_721958] .
For this study , the anesthesiologist (or comparable professionally  qualified individual , such 
as certified nurse anesthetist), who is present during the operation and administers the study  
medication, will be blinded to the reversal agent in the moderate block arms. While 
sugammadex for the deep block arm (as for the moderate block arm) will be provided to the 
anesthesiologist in masked syringe s, OR staff aware of the depth of block will know the 
study  medication as there is no approved comparator for reversal of deep block. However, 
whether the dose of sugammadex is based on ABW or IBW in the deep block groups willbe
blinded.
This study  will have a blinded safet y assessor (BSA). For any given individual subject, the 
anesthesiologist performing study  related procedures during the surgery and the BSA must be 
two separate individuals, and their roles and responsibilit ies must not overlap. The BSA, for 
any given individual subject, will not be present during the operation and will not administer 
study medication. The BSA will be blinded to study medication assignment , depth of NMB,
and drug preparation records. Of note, a BSA may , for any  other subject, fill other study  roles 
as appropriate for his/her qualifications. Note: if the BSA is not a physician, a blinded 
physician (MD, DO) will be responsible for completing the causality  assessment for all 
adverse events, including any  perioperative adverse events.
A PK-only interim analy sis (IA) will be conducted in this study  when PK data from 
approximat ely 64 evaluable sugammadex subjects becomes available. This IA will be 
conducted solely for the purpose of evaluating linearit y of sugammadex exposures in 
morbidly  obese adult subjects to inform need for study  of the 16 mg/kg dose. No unblinding 
of safety or efficacy  assessments will be done in support of this IAand enrollment will 
continue during the IA. A Standing Internal Data Monitoring Committee (siDMC)will 
review the results of the planned IA to make recommendations regarding the need to 
study   the 16 mg/kg sugammadex dose.  
Specific procedures to be performed during the trial, as well as their prescribed times and 
associated visit windows, are outlined in the Trial Flow Chart - Section 6.0. Details of each 
procedure are provided in Section 7
.0 –Trial Procedures. 
  04YY9X 
  05C8LJ
Product:   MK-8616 21
Protocol/Amendment No.: 146-[ADDRESS_986002]:   MK-8616 22
Protocol/Amendment No.: 146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
ConfidentialFigure 1Trial Design
3.0OBJECTIVE(S) & HYPOT HESIS(ES)
In male/female subjects aged 18 years or older who are morbidl y obese .
Primary Objective(s) & Hypothesis (es) 3.1
1)Objective:   To evaluate the efficacy  of sugammadex when dosed according to ABW 
as compared with IBW; specificall y, to compare the distributions of recovery  times 
pooled across depth of block and NMBA.
Hypothesis :The time to recovery  to a train- of-four (TOF )ratio of≥ 0.9 is faster in 
subjects dosed according to ABW as compared to subjects dosed according to IBW, 
pooled across depth of block and NMBA.
2)Objective:   To evaluate the safet y of sugammadex when dosed according toABW as 
compared with IBW pooled across depth of block and NMB A.
Secondary Objective(s) & Hyp othesis(es) 3.2
1)Objective :  To evaluate the efficacy  of sugammadex when dosed according to ABW 
as compared with IBW ,by [CONTACT_23992]:
The distributions of recovery  times to TOFs of  ≥0.7, ≥0.8, and ≥0.[ADDRESS_986003] deviation and geometric mean pooled across both depth of block and 
NMBA 
The proportions of subjects with prolonged recovery  (>10 minutes) pooled 
across both depth of bl ock and NMBA.
 
  04YY9X 
  05C8LJ
Product:   MK-8616 23
Protocol/Amendment No.: 146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
ConfidentialExploratory Objectives 3.3
1)Objective: To evaluate the pharmacokinetics of sugammadex in morbidly  obese 
subject s when dosed according to ABW and IBW by [CONTACT_62252] :
The geometric mean ratio (4 mg/kg versus 2 mg/kg) for the plasma dose -
normalized AUC 0-infand dose normalized Cmax following administration of 
sugamm adex based on ABW .
The geometric mean ratio (4 mg/kg versus 2 mg/kg) for the plasma dose -
normalized AUC 0-infand dose normalized Cmax following administration of 
sugammadex based on IBW .
2)Objective:   To evaluate the efficacy  of sugammadex and neostigmine; specificall y to 
compare the distributions of recovery  times in moderate depth of block pooled across 
NMBA.
3)Objective: To evaluate the efficacy  of sugammadex when dosed according to ABW
as compared with IBW ,by [CONTACT_23992] :
The distributions of recovery  times to TOFs of  ≥0.7, ≥0.8, and ≥0.[ADDRESS_986004] deviation and geometric mean separately  by [CONTACT_721959] 
The proportions of subjects with prolonged recovery  (>10 minutes) separately  by 
[CONTACT_721960] b y NMBA.
4.0BACKGROUND & RATIONA LE
Background 4.1
Refer to the Investigator’s Brochure (IB)/ approved labeling for detailed background 
information on MK- 8616 .
Pharmaceutical and Therapeutic Background 4.1.1
Sugammadex sodium, herein referred to as sugammadex ,is a modified gamma -cyclodextrin 
administered at the end of surgical procedures to reverse paral ysisinduced by [CONTACT_721961]. Sugammadex accomplishes this reversal of NMB 
through formation ofhigh affinity  sugammadex:NMBA complexes. Given the very high 
binding affinity  and 
low dissociation rate of the complex, the bound NMBAs can no longer 
act at the neuromuscular junction, thereb y restoring muscle function.  The complex is then 
renall y eliminated. Because this mechanism of action does not involve direct interaction 
with cholinergic systems, it circumvents undesired side effects associated with 
acetylcholinesterase inhibitors. Furthermore, sugammadex does not require the presence of 
neuromu scular activity  before administration ,and is therefore effective in revers al of both 
moderate and deep levels of NMB.
Sugammadex has been extensively  studied in [ADDRESS_986005]:   MK-8616 24
Protocol/Amendment No.: 146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
Confidentialcountries and marketed in more than 50 countries , with an estimated >30million exposures 
worldwide at the time of authoring of this document .
Rationale 4.[ADDRESS_986006] Population 4.2.1
The pharmacokinetics of sugammadex following single doses from 0.1 mg/kg to 96 mg/kg 
mg, calculated based upon ABW, have been extensively  evaluated across a heteroge neous 
population including the effects of intrinsic factors and extrinsic factors (drug -drug 
interactions) on sugammadex PK and/or pharmacod ynamic (PD)taking into account the 
nature of the product, results of in vitro studies, and data obtained during thedevelopment 
program.  The analysis of PK-PD included population- based analyses across many  of the 
clinical pharmacology  studies and clinical trials to assess potential covariate effects on PK-
PD variability .  Sugammadex PK is linear over doses of 0.1 to 96 mg/kg and no clinicall y 
meaningful differences in sugammadex PK based upon intrinsic factors (i.e., weight, BMI, 
gender, age, race) have been observed . In addition, similar PK was observed for anesthetized 
surgical patients and non-anesthetized health y subjects when administered sugammadex 
based on actual body  weight ,such that no dose adjustments are necessary based upon these 
factors, except in the setting of severe renal impairment or end stage renal disease. Following 
intravenous injection of sugammadex, elimination is rapid in adult and elderly  subjects 
having normal renal function, with a mean half -life of ~[ADDRESS_986007] body  weight, the increasing prevalence of 
obesity  and subsequently  the number of morbidly  obese patients undergoing surgical 
procedures 
requiring anesthesia necessitate s further evaluation of drug PK and 
pharmacod ynamic properties in the morbidly  obese (bod y mass index [BMI ]>40 kg/m2). 
Factors to consider in anesthetizing morbidly  obese individuals include the potential for 
physiological and anthropometric changes, such as increases in cardiac output, changes in 
regional blood flow, and increases in fat mass and lean mass that may affect PK properties. 
Addition ally, respi[INVESTIGATOR_721939] ,such as the increased incidence of obstructive 
sleep apnea and fat deposi tion in the oropharynx and chest wall,can alter the 
pharmacod ynamic properties of anesthetics.
Due in part to these factors and the concern for potential overdose if drug administration in 
the morbidly  obese is based on actual total body weight , alternat iveweight -based dosing 
scalars have been variously  considered (e.g. IBW, body  surface area, BMI , and lean body 
weight) .  However, administration of drugs based on IBW , for example ,can result in a 
subtherapeutic dose, because an IBW- based approach does not account for changes in body 
composition associated with obesity ; namely , the calculated IBW of a morbidly obese patient  
  04YY9X 
  05C8LJ
Product:   MK-8616 25
Protocol/Amendment No.: 146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
Confidentialis less than their actual lean body  weight that may therefore result in under- dosing (Ingrande 
and Le mmens, 20 10, [2]).  
Dosi ng based on a ctual body  weight was consistently  applied across the clinical development 
program for sugammadex , both to mirror the ABW -based dosing of the NMBAs whose 
effects it reverses and to ensure a sufficient and consistent molar ratio of 
sugammadex:NMBA . The latter effect s areliable and rapid reversal of NMB with the goal of 
minimiz ingthe occurrence of outliers experiencing prolonged recovery  of NMB and to 
reduce the risk of residual block or recurrence of block. In the pooled clinical trial 
experience, which included 157 obese patients (BMI  ≥30 kg/m2), no meaningful differences 
in efficacy  or safet y were observed in the obese ;therefore ,no dose adjustment is needed in 
the setting of obes ity. 
Data informing the use of sugammadex in the morbidly  obese is limited. The purpose of the 
current trial is to therefore evaluate the efficacy  and safet y of ABW -based and IBW -based 
dosing of sugammadex in the morbidly  obese, as well as to generate data to support potential 
dosing recommendations . 
Rationale for Dose Selection/Regimen 4.2.2
Depending on the selected NMBA and the randomly  assigned depth of NMB (moderate or 
deep), a sugammadex dose of either 2 or 4 mg/kg–established for reversa l of moderate or 
deep block, respectivel y -will be administered as an intravenous (IV) bolus dose to reverse 
NMB , with the amount of sugammadex administered to be based on either ABW or IBW .
Sugammadex exerts its effect by  [CONTACT_721962] a 1:1 ratio with rocuronium 
and vecuronium, during rocuronium- or vecuronium -induced neuromuscular blockade, the 
IV administration of sugammadex results in rapid removal of free rocuronium molecules 
from the plasma ;therefore, the molarratios and resultant concentration gradient is an 
important consideration to contextualize the dosing, based upon ABW, of sugammadex 
across populations.  At all recommended doses , based upon ABW ,of sugammadex (2 mg/kg 
at reappearance of T2, 4 mg/kg at 1-2 PTC,and 16 mg/kg at 3 minutes after 1.2 mg/kg 
rocuronium) the molar excess of sugammadex over rocuronium, at 2 minutes after 
sugammadex dosing ,is about 5 to 8.  Within these 2 minutes ,alread y enough rocuronium has 
flowed from the neuromuscular junction to the extrace llular fluid (where the concentration of 
sugammadex is still increasing) and to the plasma (where sugammadex has encapsulated free 
rocuronium first) to achieve recovery .  This creates a concentration gradient favoring the 
movement of the remaining rocuroni um molecules from the neuromuscular junction back 
into the plasma, where they are encapsulated by [CONTACT_721963], the 
neuromuscular blockade of rocuronium is terminated rapi[INVESTIGATOR_2478] y by [CONTACT_721964].  Regarding situations where 
sugammadex is needed clinically  to urgentl y reverse the effects of a large intubating dose of 
rocuronium, at 60 minutes after administration of the 16 mg/kg dose, a 4-to-[ADDRESS_986008]:   MK-8616 26
Protocol/Amendment No.: 146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
ConfidentialBased on assessments to date, including linear sugammadex PK across a dose range from 0.1 
to 96 mg/kg, this relationship of sugammadex -to-rocuronium stoichiometry  is expected to 
remain similar across demographic factors and clinical settings.  Because of this, together 
with the fact that sugammadex does not act through other receptor systems, it is anticipated 
that linear PK will be confirmed in the PK-only IA conducted in approximately  64 morbidl y 
obese subjects treated with sugammadex .  Any subsequent decision to evaluate the16 mg/kg 
dose will be based upon evaluation of PK data only;no unblinding of safety  or efficacy  will 
occur during theIA.Results of the PK-only IA will be reviewed by [CONTACT_721965] , who will 
make recommendation s regarding the need forstudy  of the 16 mg/kg sugammadex dose .
Rationale for the Use of Comparator [IP_ADDRESS]
For reversal of moderate NMB, neostigmine isselected as an active comparator because it is
the most frequentl y used acety lcholinesterase inhibitor indicated for reversal of moderate 
block. As per current prescribing information, neostigmine will be coadminist ered 
intravenously  with glycopyrrolate to counter the anticipated muscarinic effects of 
neostigmine . Neostigmine will be administered at the recommended dose of 50 µg/kg, up to 
amaximum dose of 5 mg, and glycopyrrolate will be administered at a dose of 10µg/kg. 
Hereafter , reference to the administration of “neostigmine ”herein or in other study 
documents pertains to the a dministration of neostigmine + glycopyrrolate as noted .
Because sugammadex is the only  reversal ag ent indicated for reversal of deep NMB, no deep 
block comparator is available in this trial. However, the neostigmine group will provide a 
standard -of-care comparison for the sugammadex 4mg/kg group wi threspect to safet y.
Rationale for Endpoints 4.2.3
Efficacy Endp oints [IP_ADDRESS]
During recovery  of neuromuscular transmission after blockade from an NMBA such as
rocuronium, theTOF ratio rises from zero during deep NMB back to approximately 1.0 at 
total recovery .Research demonstrates that atTOF ratiosof < 0.9, subjects are at potential 
risk for impaired phary ngeal function with associated risk of aspi[INVESTIGATOR_1516] ,and hypoxic 
ventilatory  response s are impaired at TOF ratios of < 0.7 [3]. Conversel y, recovery  to a TOF
ratio of 0.9 has been shown to correlate with essentially  complete clinical recovery  from the 
effects of NMB [4].Therefore ,in order to provide aquantitative comparative assessment of 
ABW versus IBW based dosing of sugammadex in the setting of morbid obesity ,the primary  
efficacy  parameter in this study  isthetime to recovery  of neuromuscular block to a TOF ratio 
of ≥0.9following sugammadex admi nistration .
Safety Endpoints [IP_ADDRESS]
A primary  safety  objective of this study  is an overall assessment of sugammadex safety when 
dosed according to ABW or IBW . Other safety  events (e.g., residual NMB, recurrence of 
NMB, or respi[INVESTIGATOR_50127]) and tolerability  of sugammadex will be continuously  assessed 
throughout the trial, via standard AEreporting.  
  04YY9X 
  05C8LJ
Product:   MK - 8616 27
Protocol/Amendment No.: 146-[ADDRESS_986009] 30 minutes after administration of study  medication to facilitate arrhythmia 
assessment .
For the purpose of this study : 
Treatment emergent sinus bradycardia is defined as meeting allof the following:
oa heart rate <60 bpm
oa heart rate decrease dmore than 20% compared to the subject’s baseline heart 
rate value
ois sustained for at least 1 minute after administration of study  medication . 
Treatment emergent sinus tachycardia is defined as meeting all of the following:
oa heart rate >100 bpm
oa heart rate increase dmore than 20% compared to the subject’s baseline heart 
rate value
ois sustained for at least 1 minute after administration of study medication.
Other treatment emergent cardiac arrhythmias are defined as meeting allof the 
following:
onew or worsening arrhythmias (e.g., atrial fibrillation, atrial tachy cardia, 
ventricular fibrillation, or ventricular tach ycardia )
ois sustained for at le ast one minute after administration of study  medication .
*Baseline heart rate is defined as the heart rate taken after the last dose of NMBA is 
administered and (approximately  5 minutes
)prior to administration of study medication.
To ensure timely  reporti ng and comprehensive data collection regarding ECIs, the following 
types of events are prespecified as ECIs:  
Clinically relevant sinus bradycardia is defined as any brady cardia event 
necessitating intervention, as determined b y investigator judgment .
Clinically relevant sinus tachycardia is defined as any tachy cardia event 
necessitating intervention, as determined b y investigator judgment .
Other clinically relevant cardiac arrhythmias aredefined as any arrhy thmia event 
necessitating intervention, as determined b y investigator judgment. 
Hypersensitivity and/or anaphylaxis
Events of hypersensitivity  and anaphy laxis (defined by [CONTACT_49732][5]) will be 
adjudicated by [CONTACT_721966] .
Any perioperative events that occur in the OR or PACU will be recorded by [CONTACT_721967].  
  04YY9X 
  05C8LJ
Product:   MK-8616 28
Protocol/Amendment No.: 146-[ADDRESS_986010] safety assessments (e.g., physical examination, vital signs including h eart 
rate and blood pressure )will be recorded at specified time points (see Trial Flow Chart -
Section 6.0 ). 
Pharmacokinetic Endpoints [IP_ADDRESS]
The intended use for sugammadex is single intravenous administration as needed.  Therefore, 
consistent with historical assessments and based upon its pharmacokinetic properties, 
pharmacokinetic sampling following sugammadex administration at selected time points 
through at least 4-[ADDRESS_986011]-dose will support evaluation of exposure (AUC [ADDRESS_986012], Cmax),as well as clearance (CL), volume of distribution (Vd) ,apparent terminal 
elimination half -life (t 1/2),and assessment of PK linearit y.  
Population -based methods of analysis may be explored at the completion of the study  to 
further characterize the PK profiles within morbidly  obese subjects and/or permit 
comparisons to historical data.  
For all subjects, blood samples will be collected at specific visits as indicated in the Trial 
Flow Chart (Section 6.0).
The final decision as to which plasma samples will be assay ed will be made by [CONTACT_1034]'s 
Department of Pharmacokinetics, Pharmacod ynamics, and Drug Metabolism [COMPANY_003]M and the 
Clinical Monitor.
Information regarding the collection and shippi[INVESTIGATOR_721940].
Future Biomedical Research [IP_ADDRESS]
The Sponsor will conduct Future Biomedical Research on DNA specimens consented for 
future biomedical research during this clinical trial.
Such research is for biomarker testing to address emergent questions not described elsewhere 
in the protocol (as part of the main trial) and will only be conducted on specimens from 
appropriatel y consented subjects. The objective of collecting /retaining specimens for Future 
Biomedical Research is to explore and identify  biomarkers that inform the scientific 
under standing of diseases and/or their therapeutic treatments. The overarching goal is to use 
such information to develop safer, more effective drugs /vaccines , and/or to ensure that 
subjects receive the correct dose of the correct drug /vaccine at the correct time.  The details 
of this Future Biomedical Research sub-trial are presented in Section 12.2 –Collection and
Management of Specimens for Future Biomedical Research.
Benefit/Risk 4.[ADDRESS_986013] benefit from treatment
during participation, as clinical trials are designed to provide information about the safety 
and effectiveness of an investigational medicine.
Sugammadex has a positive benefit -risk profile and is well tolerated in the approved 
indications as described in the Investigator’s Brochure. It has specifically been shown to be  
  04YY9X 
  05C8LJ
Product:   MK-8616 29
Protocol/Amendment No.: 146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
Confidentialsuperior (faster and effective in a higher proportion of treated subjects) to both placebo and 
neostigmine for reversal of moderate anddeep NMB. Reversal of deep NMB is a unique 
benefit of sugammadex unavailable with current ly available treatments. From a risk 
perspective, sugammadex has been shown to be generall y safe and well tolerated. The use of 
sugammadex at recommended doses is associated with a low risk of residual NMB or 
recurrence of NMB compared with other treatment. The clinical trial experience with 
sugammadex (with [ADDRESS_986014] IV exposures) is consistent with and supported by [CONTACT_447]-
marketing data obtained in real world use in clinical practice (with more than an estimated 30 
million patients exposed in more than 50 countries). 
Additional details regarding specific benefits and risks for subjects participating in this 
clinical trial may  be found in the accompan ying IB and Informed Consent documents.
5.0METHODOLOGY
Entry Criteria 5.1
Diagnosis/Condition for Entry into the Trial 5.1.1
Male/f emale subjects aged [ADDRESS_986015]:
1.Have BMI ≥ 40 kg/m2 (morbidly  obese) .
2.Be categorized asAmerican Societ y of Anesthesiologists (ASA) Physical Status 
Class 3 ,as determined by  [CONTACT_737] [6].
3.Have a planned surgical procedure that requires neuromuscular block with either 
rocuronium or vecuronium .
4.Have a planned surgical procedure (e.g., gastrointestinal [GI], urologic, or 
laparoscopic procedures) that in the opi[INVESTIGATOR_721941] (maintained by 
[INVESTIGATOR_1312]-dosing or con tinuous infusion). 
5.Have a planned surgical procedure that would allow objective neuromuscular 
monitoring techniques to be applied with access to the arm for neuromuscular 
transmission monitoring (NMTM) .
6.If female, who is not of reproductive potential ,be one of the following: (1) 
postmenopausal (defined as at least 12 months with no menses in women ≥45 years 
of age); (2) has had a hysterectom y and/or bilateral oophorectomy , bilateral 
salpi[INVESTIGATOR_1656] , or bilateral tubal ligation/occlusion at least 6 weeks prior to screening; 
(3) has a congenital or acquired condition that prevents childbearing ; or (4) is 
undergoing surgical sterilization as the planned surgical procedure associated with 
participation in this study (e.g., h ysterectomy  or tubal ligation) .  
  04YY9X 
  05C8LJ
Product:   MK-8616 30
Protocol/Amendment No.: 146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
Confidential7.If femal e, who is sexually  active and of child -bearing potential ,agree sto use a 
medically  accepted method of contraception through seven days after receiving 
protocol -specified medication. Medically  accepted methods of contraception include 
condoms (male or female) with a spermicidal agent, diaphragm or cervical cap with 
spermicide, medicall y prescribed intrauterine device (IUD), inert or copper -
containing IUD, surgical sterilization (e.g., hysterectom y or tubal ligation).   
Abstinence (relative to heteros exual activity ) can be used as the sole method of 
contraception if it is consistently  employ ed as the subject’s preferred and usual 
lifesty le and if considered acceptable by [CONTACT_551698]/I RBs.  
Periodic abstinence (e.g., calendar, ovulation, sympto -thermal, post-ovulation 
methods, etc.) and withdrawal are not acceptable methods of contraception. 
If a contraceptive method listed above is restricted by [CONTACT_427]/guidelines, 
then it does not qualify  as an acceptable method of contraception for subjects 
participating at sites in this country/region.
8.Be able to provide (or the subject’s legall y authorized representative in accordance 
with local requirements ), written informed consent for the trial. The subject or
legally  authorized representative may also provide consent for Future Biomedical 
Research.  However, the subject may participate in the main trial without 
participating in Future Biomedical Research .
Subject Exclusion Criteria 5.1.[ADDRESS_986016]:
1.Has an actual bod y weight < 100 kg.
2.Has a pacemaker or automatic implantable cardioverter -defibrillator (AICD) that 
precludes the assessment of brad ycardia or arrh ythmias. 
3.Has a medical condition or surgica l procedure that precludes reversal of 
neuromuscular block at the end of surgery.
4.Has neuromuscular disorder(s) that may affect neuromuscular block and/or trial 
assessments. 
  04YY9X 
  05C8LJ
Product:   MK - 8616 31
Protocol/Amendment No.: 146-01 
MK-8616-146-01 Final Protocol 5-Jul- 2018
Confidential5.Is dial ysis-dependent or has severe renal insufficiency .
Note:   If dialysis or severe renal insufficiency is not known or confirmed in the 
subject’s medical history , a creatinine clearance value should be calculated based 
upon serum creatinine values obtained from local labs within the past 2 weeks prior to 
Visit 1 or local labs performed between V1 and V2 (e.g., pre- operative testing). 
Severe renal insufficiency  is defined as an estimated creatinine clearance of <30 
mL/min using the formulas below.
Cockcroft -Gault formula:
For Males:   Creatinine Clearance  =         (140-age[yr]) x w eight (kg)
        serum creatinine (mg/dL) x72
For Females:   Creatinine Clearance  =   0.85 x (140- age[y r]) x w eight (kg)
          serum creatinine (mg/dL) x72
6.Has or is suspected of having a personal history  or family  history (parents, 
grandparents, or siblings) of malignant h yperthermia.
7.Has or is suspected of having an allergy  (e.g., hypersensitivity  and/or anaphylactic 
reaction) to study  treatments or its/their excipi[INVESTIGATOR_840], to opi[INVESTIGATOR_2438]/opi[INVESTIGATOR_858], muscle 
relaxants or their excipi[INVESTIGATOR_840], or other medication(s) used during general anesthesia.
8.Has received or is planned to receive toremifene within 24hours before or within 24 
hours after stud y medication administration.
9.Has an y cond ition that would contraindicate the administration of study  medication .
10.Is pregnant, is attempting to become pregnant, or is lactating .
11.Has any clinicall y significant condition or situation (e.g.,anatomical malformation 
that complicates intubation) other than the condition being studied that, in the opi[INVESTIGATOR_8574], would interfere with the trial evaluations or optimal participation 
in the trial .
12.Is currently  participating in or has participated in aninterventional clinical trial with 
an inves tigational compound (including any other current or ongoing trial with a 
sugammadex treatment arm) or device within 30 daysof signing the informed consent 
form of th
iscurrent trial.
13. Is or has an immediate family  member (e.g., spouse ,parent/ legal guardian, sibling or 
child) who is investigational site or sponsor staff directly  involved with this trial. 
  04YY9X 
  05C8LJ
Product:   MK-8616 32
Protocol/Amendment No.: 146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
ConfidentialTrial Treatment(s) 5.2
The t reatment (s)to be used i n this trial are outlined below in Table 1.
Table 1 Trial Treatment
Drug Dose/PotencyDose 
FrequencyRoute of 
AdministrationTreatment 
PeriodUse
Sugammadex 2 mg/kg ABW Single dose IV Peri-anesthetic 
periodExperimental
Sugammadex 2 mg/kg IBW Single dose IV Peri-anesthetic 
periodExperimental
Sugammadex 4 mg/kg ABW Single dose IV Peri-anesthetic 
periodExperimental
Sugammadex 4 mg/kg IBW Single dose IV Peri-anesthetic 
periodExperimental
Neostigmine + 
Glycopyrrolate 50 µg/kg (up 
to 5 mg 
maximum 
dose)
10 µg/kg
(up to 1 mg 
maximum 
dose)Single dose IV Peri-anesthetic 
periodComparator / 
standard of 
care
Trial Treatment should begin within [ADDRESS_986017]’s scheduled surgery  or one day in advance of the 
scheduled surgery .  Sites should contact [CONTACT_570755] a subject‘s surgery is postponed for 
more than one day from the date the subject is randomized in IVRS (e.g., surgery  postponed 
due to subject illness).  Trial status of subjects in these situations will be handled on a case b y 
case basis in consul tation with the Sponsor.
The investigator shall take responsibility  for and shall take all steps to maintain appropriate 
records and ensure appropriate suppl y, storage, handling, distribution and usage of trial 
treatments in accordance with the protocol and an y applicable laws and regulations.
Dose Selection 5.2.1
Dose Selection (Preparation) [IP_ADDRESS]
The rationale for selection of doses to be used in this trial is provided in Section 4.0 –
Background & Rationale. Specific calculations or evaluations required to be performed in 
order to administer the proper dose to each subject are outlined in the Study  Operations 
Manua l (or equivalent).
Sugammadex will be given at 2mg/kg for moderate block or 4mg/kg for deep bloc k based on 
randomly  assigned level of block. Additionally , sugammadex will be dosed by[CONTACT_721968]  
  04YY9X 
  05C8LJ
Product:   MK-8616 33
Protocol/Amendment No.: 146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
ConfidentialIBW , according to randomly  assigned treatment group. IBW will be calculated by [CONTACT_721969], 2015: Males: 142 lb+3 lb/in over 63inches +1 
lb/in over 71inches . Females: 119 lb+3 lb/in. over 60inches [1].Height will be rounded to 
the nearest whole integer before appl ying the Kammerer formula .
Sugammadex, neostigmine and glycop yrrolate will be prepared by [CONTACT_21703]
(or delegate) and supplied to OR staff in masked syringe sfor administration to study  
subjects .
The volume of study  medication drawn into the syringes will benormalized between 
treatment groups by [CONTACT_721970]. Instructions for normalizing the volumes are included in a 
separate Study  Drug Manual . 
Timing of Dose Administrati on 5.2.2
Trial treatment should begin within 1 day  of randomization in I VRS.
The total duration of administration for all study  medication syringes (Dose 1 and Dose 2 
syringe(s) as outlined in Study  Drug Manual )should not exceed a total of [ADDRESS_986018] dose of administered NMBA and within 2 minutes ofdetection of reappearance of T2
with a lower limit of train of four ( TOF )count [ADDRESS_986019] dose of 
administered NMBA and within 2 minutes ofdetec tion of a target of 1 -2 PTC with a range of 
1-5 PTC anda TOF count of 0 .
Trial Blinding 5.2.3
Study Medication Blinding
Sponsor study  team personnel will be blinded to study  medication assignments for 
randomized subjects, with the exception of designated Spon sor personnel (e.g., unblinded 
Clinical Research Associates [CRAs], the pharmacokineticist, statistician(s) not associated 
with the study  who will complete the PK IA and provide the data to the siDMC, and other 
designated individuals as required) .
The official final database will not be unblinded until medical/scientific review has been 
performed, protocol deviations have been identified, and data have been declared final and 
complete.
The site pharmacist (or delegate) will be unblinded to study  medication assignments in 
order to prepare study  medication.  Study medication will be provided to site staff in the OR 
(anesthesiologist) in masked syringe sto ensure that the contents of the syringe swill not be 
revealed.  
  04YY9X 
  05C8LJ
Product:   MK - 8616 34
Protocol/Amendment No.: 146-[ADDRESS_986020] (or comparable professionally  qualified individual , such as certified 
nurse anesthetist), and other OR staff will be blinded to the reversal agent in the moderate 
block arms. While sugammadex for the deep block arm will be provided to the OR 
(anesthesiologist) in masked syringe s, OR staff aware of the depth of block will know the 
study  medication as there is no approved comparator for reversal of deep block, but will not 
know if sugammadex dosing is based on ABW or IBW .Regardless of level of block, study  
personnel in the OR will be blinded to the dose assignment.
The blinded safety assessor (BSA )will be an appropriatel y qualified health care 
professional (e.g., a licensed physician, nurse practitioner, physician assistant, or certified 
registered nurse anesthetist [or comparable professional qualification in countries outside of 
the [LOCATION_002]]) with training and experience in anesthesia or post -anesthesia care.   
The BSA for an y given individual subject will be blinded to:
o Study  medication assignment
o The depth of NMB  
o Drug preparation records 
The BSA for an y given individual subject will:
o Not be present during the operation and will not administer study 
medication
o Conduct the required procedures (see Section 6.0 Trial Flow Chart) at the 
post-anesthetic safet y visit (Visit 3)
o Complete the causalit y assessment for all adverse events including
perioperative adverse events. Note: if the BSA is not a physician, a blinded 
physician (MD, DO),not present during the surgical procedure, reversal 
dosing, or recovery  for given subject ,will be responsible for completing the 
causality  assessment for all adverse events.
o Be required to sign a statement for each subject (after V4 or discontinuation) 
confirming that the blind was maintained (treatment group , depth of block, 
drug preparation records , and TOF -Watch SX®traces ).
Of note, a BSA may, for any other subject, fill other study  roles as appropriate for 
his/her qualifications.
The anesthesiologist performing study -related procedures during surgery  and the BSA must 
be [ADDRESS_986021]. Any inadvertent unblinding of the BSA will be documented.
PK-only Interim Analysis Blinding
An IAof PK data will be conducted to inform the need for study of the16 mg/kg dose after 
the completion of approximate ly [ADDRESS_986022]:   MK-8616 35
Protocol/Amendment No.: 146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
Confidentialaccess to the interim dataset and the individual results. No unblinding of safet y or efficacy 
will occur in support of this PK -only IA.
See Section 7.1.4. 1.3, Blinding/Unblinding, for a description of the method of unblinding a 
subject during the trial, should such action be wa rranted.
Randomization or Treatment Allocation 5.3
Randomizatio n will occur centrall y using IVRS . Within each NMBA stratum (rocuronium 
or vecuronium), s ubjects will be randomiz edto one of 5 treatment groups as indicated in the 
Trial Diagram ( Figure 1in Section 2. 2). 
Subjects will be assigned randomly  on Da y 1 in a 1:1:1:1:1 ratio :
1.Moderate block and reversal with sugammadex 2 mg/kg , dosed b y ABW
2.Moderate block andreversal with sugammadex 2 mg/kg , dosed b y IBW
3.Moderate block andreversal with neostigmine 50µg /kg+ glycopyrrolate 10 µg/kg by 
[CONTACT_721971]
4.Deep block andreversal with sugammadex 4 mg/kg , dosed b y ABW
5.Deep block andreversal with sugammadex 4 mg/kg , dosed b y IBW
Stratification 5.4
Treatment allocation/r andomization will be stratified according to the following factors:
NMBA (rocuronium or vecuronium)
Subjects will be stratified by  [CONTACT_721972] (approximately  30% of the overall planned 
sample size will be enrolled in the vecuronium stratum ).
Concomitant Medications /Vaccinations (Allowed & Prohibited) 5.5
Medications or vaccinations specifically  prohibited in the exclusion criteria are not allowed 
during the ongoing trial. If there is a clinical indicat ion for any medication or vaccination 
specificall y prohibited during the trial, the investigator should discuss this with the Sponsor 
Clinical Director. The final decision on any supportive therap y or vaccination rests with the 
investigator and/or the sub ject's primary  physician.
Rocuronium or vecuronium, are concomitant medications to be used per label as adjunct to 
general anesthesia .Besides rocuronium and vecuronium ,a subjec t must not be administered 
any other NMBA sduring the trial , including :
Other steroidal NMBA s such as pa ncuronium 
Nonsteroidal NMBA s,such as succiny lcholine or benzy lisoquinolinium compound
(e.g., cisatracurium ) *
Toremifene use within 24hours before or within 24hours after study  medication
administration is prohibited . 
  04YY9X 
  05C8LJ
Product:   MK-8616 36
Protocol/Amendment No.: 146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
Confidential*Except in the circumstance that renewed muscle relaxation is needed after administration of study 
medication , in which case a non -steroidal NMBA should be administered.
Rescue Medications & Supportive Care 5.6
No rescue or supportive medications are specified to be used in this trial.
Diet/Activity/Other Considerations 5.[ADDRESS_986023]’s legally  acceptable 
representative withdraws consent from the trial.
If a subject withdraws from the trial, they will notreceive treatment or be followed at 
scheduled protocol visits.
Specific details regarding procedures to be performed at the time of withdrawal from the trial 
including the procedures to be performed should a subject fail to return for scheduled visits 
and/or if the study  site is unable to contact [CONTACT_423], as well as specific details regarding 
withdrawal from Future Biomedical Research are outlined in Section 7.1.4 –Other 
Procedures.
Subject Replacement Strategy 5.[ADDRESS_986024] to follow -up (i.e. the subject is unable to be contact[CONTACT_551701]).
Clinical Criteria for Early Trial Termination 5.[ADDRESS_986025]:   MK - 8616 37
Protocol/Amendment No.: 146-01 
MK-8616-146-01 Final Protocol 5-Jul- 2018
Confidential6.0TRIAL FLOW CHART
Trial Period: Screening Treatment Follow -up
Visit Number/ Title:[ADDRESS_986026]-anesthetic Visita4
Follow -up Safety 
Contactb
Scheduled Da y:Between Days
-21to 1Day 1
(Day of Surgery)Days 1 to 2
(4to 36hours post study 
medication administration)[ADDRESS_986027] study 
medication administration
Scheduling Window , Days: -21toDay 1 ±0 days See footnote “ c” +2 days
Visit 1 and Visit 2 may occur on the same day .
Visit 2 may occur across 2 days.
Refer to Section [IP_ADDRESS]
Administrative Procedures
Informed Consent X
Informed Consent for Future Biomedical Research X
Inclusion/Exclusion Criteria X X
Subject Identification Card X Xd
Medical History X
Concomitant Medication Review X X X X
Screening Number Assignment X
RandomizationeX
Clinical Procedures/Assessments
Physical Examination X Xa
Height X
Weight and BMI calculation X X
12-lead Electrocardiogram X 
  04YY9X 
  05C8LJ
Product:   MK - 8616 38
Protocol/Amendment No.: 146-01 
MK-8616-146-01 Final Protocol 5-Jul- 2018
ConfidentialTrial Period: Screening Treatment Follow -up
Visit Number/ Title:[ADDRESS_986028]-anesthetic Visita4
Follow -up Safety 
Contactb
Scheduled Da y:Between Days
-21to 1Day 1
(Day of Surgery)Days 1 to 2
(4to 36hours post study 
medication administration)[ADDRESS_986029] study 
medication administration
Scheduling Window , Days: -21toDay 1 ±0 days See footnote “ c” +2 days
Visit 1 and Visit 2 may occur on the same day .
Visit 2 may occur across 2 days.
Refer to Section [IP_ADDRESS]
Continuous ECG Monitoring Xf
Vital Signs (heart rate, respi[INVESTIGATOR_697], O2saturation, 
blood pressure , temperature )X XgX
Administration of NMB A X
Administration of Study Medication X
Neuromuscular M onitoringhX
Adverse Events/ECI Monitoring X X XaX
Adverse Device E vents X
Laboratory Procedures/Assessments
HematologyiX X
ChemistryiX X
Blood Samples for Pharmacokinetics XjXj
Pregnancy TestkX Xk
Blood (DNA) for Future Biomedical Researchl X 
  04YY9X 
  05C8LJ
Product:   MK - 8616 39
Protocol/Amendment No.: 146-01 
MK-8616-146-01 Final Protocol 5-Jul- 2018
ConfidentialTrial Period: Screening Treatment Follow -up
Visit Number/ Title:[ADDRESS_986030]-anesthetic Visita4
Follow -up Safety 
Contactb
Scheduled Da y:Between Days
-21to 1Day 1
(Day of Surgery)Days 1 to 2
(4to 36hours post study 
medication administration)[ADDRESS_986031] study 
medication administration
Scheduling Window , Days: -21toDay 1 ±0 days See footnote “ c” +2 days
Visit 1 and Visit 2 may occur on the same day .
Visit 2 may occur across 2 days.
Refer to Section [IP_ADDRESS]
aThe physical exam and adverse event review must be completed by [CONTACT_721973] (BSA) at V3. For any given indivi dual subject, the anesthesiologist performing 
study related procedures during the surgery and the BSA must be [ADDRESS_986032]’s scheduled surgery 
(except when V1 and V2 occur on the same day). Sites should contact [CONTACT_570755] a subject‘s surgery is postponed for more than [ADDRESS_986033] is 
randomized in IVRS (e.g., surgery postponed due to subject illness). Trial status of subjects in these situations will be handled on a case by [CONTACT_721974].
fTo occur from  [ADDRESS_986034] 30 minutes following administration of study medication.
gTo be performed pre -administration of NMBA, approximately 5 minutes  prior to study medication administration and at 2, 5, 10, 30, 45, and 60 min utes after study medication 
administration. 
h Neuromuscular monitoring using TOF -Watch SX®: Until recovery of TOF to ≥ 0.9.
iLaboratory samples will be sent to a central laboratory for analysis. Baseline safety labs should be obtained from the same port and at the time of the first PK draw. Post-op 
safety labs should be obtained at the time of the 4 -6 hour PK draw.
j PK: Sample drawn before NMBA administration, and at 2, 5, 15, 60, and 120 minutes, 4-6 hours and 10-12 hours after administration of study medication reversal agent. Note 
that the 10 -12 hour PK draw may not be feasible depending on length of hospi [INVESTIGATOR_4408]; however, if the subject remains hospi[INVESTIGATOR_721942] 
10-[ADDRESS_986035] (performed locally) 
is required if the urine pregnancy test is positive, unless local requirements require otherwise. Note that if the pregnancy test is done within [ADDRESS_986036] the DNA sample. The blood (DNA) for future biomedical research sample should be take n 
on Day 1 at the same time as other blood collections. If the sample cannot be taken at this visit, it can be taken at the nex t scheduled blood draw.
Abbreviations:  BMI = Body mass index; NMBA = Neuromuscular blocking agent; ECI = Events of clinical interest; β-hCG = Serum beta human chorionic gonadotropin;
DNA = Deoxyribonucleic acid; BSA = Blinded Safety Assessor 
  04YY9X 
  05C8LJ
Product:   MK-8616 40
Protocol/Amendment No.: 146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
Confidential7.0TRIAL PROCEDURES
Trial Procedures 7.1
The Trial Flow Chart -Section 6.0summarizes the trial procedures to be performed at each 
visit.  Individual trial procedures are described in detail below.  It may be necessary  to 
perform these procedures at unscheduled time points if deemed clinically necessary  by [CONTACT_1275].
Furthermore, additional evaluations/testing may  be deemed necessary  by [CONTACT_26357] . In some cases, such evaluation/testing 
may bepotentially sensitive in nature (e.g., HIV, Hepatitis C, etc.), and thus local regulations 
may require that additional informed consent be obtained from the subject.  In these cases, 
such evaluations/testing will be performed in accordance with those regu lations.
Administrative Procedures 7.1.1
Informed Consent [IP_ADDRESS]
The investigator or qualified designee must obtain documented consent from each potential 
subject or each subject’s legally  acceptable representative prior to participating in a clinical 
trial or Future Biomedical Research .If there are changes to the subject’s status during the 
trial (e.g. ,health or age of majority  requirements ), the investigator or qualified designee must 
ensure the ap propriate consent is in place. 
[IP_ADDRESS].[ADDRESS_986037]’s dated signature [INVESTIGATOR_4388] [CONTACT_423]’s legally 
acceptable representative’s dated signature [INVESTIGATOR_2394] a consent form along with the dated signature 
[CONTACT_63564]. 
A copy  of the signed and dated consent form should be given to the subject before 
participation in the trial.
The initial informed consent form, any subsequent revised written informed consent form 
and any written information provided to the subject must receive the IRB/ERC’s 
approval/favorable opi[INVESTIGATOR_19349].  The subject or his/her legally  acceptable 
representative should be informed in a timel y manner if new information becomes available 
that may be relevant to the subject’s willingness to continue participation in the trial.  The 
communication of this information will be provided and documented via a revised consent 
form or addendum to the original consent form that captures the subject’s dated signature [CONTACT_90096] [CONTACT_423]’s legall y acceptable representative’s dated si gnature.
Specifics about a trial and the trial population will be added to the consent form template at 
the protocol level.  
The informed consent will adhere to IRB/ERC requirements, applicable laws and regulations 
and Sponsor requirements. 
  04YY9X 
  05C8LJ
Product:   MK-8616 41
Protocol/Amendment No.: 146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
Confidential7.[IP_ADDRESS] Consent and Co llection of Specimens for Future Biomedical Research
The investigator or qualified designee will explain the Future Biomedical Research consent 
to the subject, answer all of his/her questions, and obtain written informed consent before 
performing an y proce dure related to the Future Biomedical Research sub -trial.  A copy  of the 
informed consent will be given to the subject.
Inclusion/Exclusion Criteria [IP_ADDRESS]
All inclusion and exclusion criteria will be reviewed at Visit [ADDRESS_986038] [IP_ADDRESS]
All subjects will be given a Subject Identification Card identify ing them as participants in a 
research trial. The card will contain trial site contact [CONTACT_3031] (inclu ding direct telephone 
numbers) to be utilized in the event of an emergency . The investigator or qualified designee 
will provide the subject with a Subject Identification Card immediately  after the subject 
provides written informed consent. At the time of treatment allocation/randomization, site 
personnel will add the treatment/randomization number to the Subject Identification Card.
The subject identification card also contains contact [CONTACT_75345] a health care provider can obtain information about trial 
medication/vaccination in emergency  situations where th e investigator is not available.
Medical History [IP_ADDRESS]
A medical history  will be obtained by [CONTACT_27404] .The surgical 
procedure and medical indication for surgery should be recorded in the Sponsor database .
Prior and Concomitant Medications Review [IP_ADDRESS]
[IP_ADDRESS].[ADDRESS_986039] 
within 14 days before starting the trial. See Section 5.5 for concomitant medication 
information. 
[IP_ADDRESS].[ADDRESS_986040] any medication (e.g., beta blockers, 
calcium channel blockers , anti-arrhythmic agents )taken by [CONTACT_721975] [ADDRESS_986041]:   MK-8616 42
Protocol/Amendment No.: 146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
ConfidentialAssignment of Screening Number [IP_ADDRESS]
All consented subjects will be given a unique screening number that will be used to identify 
the subject for all procedures that occur prior torandomization or treatment allocation.  Each 
subject will be assigned only one screening number.  Screening numbers must not be re -used 
for different subjects.
Any subject who is screened multiple times will retain the original screening number 
assigned a t the initial screening visit.
Specific details on the screening visit requirements (screening/rescreening) are provided in 
Section [IP_ADDRESS].  
Assignment of Treatment/ Randomization Number [IP_ADDRESS]
All eligible subjects will be randoml y allocated and will receive a treatment/ randomization 
number.  The treatment/ randomization number identifies the subject for all procedures 
occurring after treatment allocation/ randomization.  Once a treatment/ randomization number 
is assigned to a subject, it can never be re -assigned t o another subject.
A single subject cannot be assigned more than 1 treatment/ randomization number.
Trial Compliance (Medicatio n) [IP_ADDRESS]
Compliance with dosage will bebased on the actual dosage of study  medication 
administered versus assign eddosage. For further information, refer to Section 8.11.
Clinical Procedures/Assessments 7.1.2
Physical Examination [IP_ADDRESS]
The principal investigator [INVESTIGATOR_721943] (i.e., phy sician, ph ysician’s assistant, or nurse 
practitioner) will perform a general phy sical examinati on of the following organ s ystems at 
Visit 1 : 
Head, E yes, Ears, Nose, and Throat
Neck
Respi[INVESTIGATOR_36517]
Cardiovascular s ystem
Abdomen
Skin and extremities
Neurological system, including mental status, motor strength, muscle tone, sensation, 
and reflexes . 
Any medical conditions found during the Screening physical exam will be recorded in the 
Sponsor database. 
  04YY9X 
  05C8LJ
Product:   MK-8616 43
Protocol/Amendment No.: 146-[ADDRESS_986042] physical examination (Screening) will be 
recorded in the Sponsor database .
Body Weight and Height [IP_ADDRESS]
Body weight and height will be collected and recorded in the Sponsor database . 
Measurements should be rounded to the nearest whole number . Body  weight will be obtained 
without shoes and with heav y clothing (e.g., jacket or coat) removed. 
IBW will be calculated by [CONTACT_721976], 2015: Males: 142 
lb +3 lb/in over 63 inches +1 lb/in over 71 inches.  Females: 119 lb +3 lb/in. over 60 inches 
[1].
Body Mass Index [IP_ADDRESS]
Body mass i ndex will be calculated at Visit 1 and Visit 2 (only once if V1 and V2 are 
conducted on the same day )to ensure that subjects meet eligi bility criteri a. 
The formula for BM I is weight in kilograms divided by [CONTACT_55739] (kg/m2). 
Electrocardiogram [IP_ADDRESS]
Visit 1 :
A 12-lead ECG will be performed at Visit 1 for documentation of baseline rhythm and 
cardiac disease. Historical ECGs (those done prior to informed consent) are not acceptable .
To assist sites with scheduling study  procedures, the screening ECG may be performed at 
Visit [ADDRESS_986043] be performed prior to induction of anesthesia or prior 
to administratio n of study medication. 
Visit 2 : 
During the peri-anesthetic visit, continuous ECG monitoring will occur at least 5 minutes 
before, during, and for 30 minutes after administration of study  medication (sugammadex or 
neostigmine) to identify events of treatm ent emergent sinus bradycardia, treatment emergent 
sinus tachy cardia, or other treatment emergent cardiac arrhy thmias, which will be recorded in 
the Sponsor database . Sites should also record the heart rate and associated blood pressure 
for these events.
Events of clinicall y relevant sinus brady cardia, clinical relevant sinus tachy cardia, or other 
clinically relevant cardiac arrhy thmias (according to the definitions in Section [IP_ADDRESS]) should 
be reported as ECIs in the Sponsor database. 
Printing of the ECG trace is not required per protocol .
Vital Signs [IP_ADDRESS]
Heart rate, blood pressure, respi[INVESTIGATOR_2842], ox ygen saturation, and temperature will be 
obtained at the following time points shown in Table 2. 
  04YY9X 
  05C8LJ
Product:   MK - 8616 44
Protocol/Amendment No.: 146-[ADDRESS_986044] dose of NMBA is 
administered and (approximately 
5 minutes) prior to administration 
of study medicationAt 2, 5, 10, 30, 45, and 60 
minutes following 
administration of study 
medication
HR X X X X X
BP X X X X X
RR X X X X X
O2saturation X X X X X
Body 
Temperature :
Obtained per l ocal 
guidelines/ standard 
methods, except 
when noted*X X X
*Required c ore body 
temperaturea, bX X
aThe target core body temperature is ≥ 35ºC (95ºF). 
bThe only acceptable locations for core body temperature measurement are:  nasopharynx, esophagus, bladder, pulmonary artery b ranch, or rectum. 
Abbreviations: BP= blood pressure, HR= heart rate, NMBA = n euromuscular blocking agent , 02= oxygen , RR= respi[INVESTIGATOR_92196] 
  04YY9X 
  05C8LJ
Product:   MK-8616 45
Protocol/Amendment No.: 146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
ConfidentialAdministration of Neuromuscular Blocking Agents [IP_ADDRESS]
NMBA swill be dosed as indicated per prescribing information for intubation purposes and 
maintenance of neuromuscular block b y re-dosing or continuo us infusion.    
Only  one NMBA should be used for the entire duration of surgery , including the intubation 
dose.   The NMBA used during surgery  should be the NMBA as noted in the IVRS
confirmation .
Neuromuscular Monitoring [IP_ADDRESS]
Details for NMTM training and site personnel qualification, set-up, calibration, data 
collection, etc.are provided in the Neuromuscular Transmission Monitoring Guidelines
provided separatel y.  Neuromuscular monitoring will be performed using a TOF -Watch SX®, 
which will be provided to participating sites with all required accessories and components . 
After inducti on of anesthesia, neuromuscular monitoring will start before the administration 
of NMBA . Neuromuscular monitoring should remain ongoing until the subject reaches the 
endpoint of TOF ≥0.9, or for at least 30minutes following administration of study  drug.In 
instances where a return to TOF ≥0.[ADDRESS_986045]’s medical requirements .
In the event that TOF -Watch SX®data become unavailable due to device malfunction ,follow 
the general guidance:
If prior to Study  Medication administration the TOF -Watch SX®data become 
unavailable due to device malfunction, then the investigator should discontinue the 
study  subject fro m the protocol and proceed per usual care.
If after Study  Medication administration the TOF -Watch SX®data become 
unavailable due to device malfunction, the study  subject should continue in the study , 
but the investigator should discontinue TOF -Watch SX®monitoring and use clinical 
judgment to determine when it is appropriate to extubate the subject. All other study 
procedures should be completed through Visit 4 (Follow -up Safet y Contact) .
Laboratory Procedures/Assessments 7.1.3
Details regarding specific laboratory  procedures/assessments to be performed in this trial are 
provided below. The total amount of blood to be drawn/collected over the course of the trial 
(from pre-trial to post-trial visits), including approximate blood volumes drawn/collected by 
[CONTACT_721977] t ype per subject can be found in Section 12.3. 
  04YY9X 
  05C8LJ
Product:   MK-8616 46
Protocol/Amendment No.: 146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
ConfidentialLaboratory Safety Evaluations (Hematology and Chemistry) [IP_ADDRESS]
Laboratory  tests for hema tology  and chemistry are specified in Table [ADDRESS_986046]
Hemoglobin Alkaline phosphatase Serum β-human chorionic 
gonadotropin (β -hCG)
Platelet count Alanine aminotransferase 
WBC (total and 
differential)Aspartate aminotransferase 
Bicarbonate
Calcium
Chloride
Creatinine
Glucose
Phosphorus
Potassium
Sodium
Total Bilirubin  
Direct Bilirubin, if total bilirubin 
is elevated above the upper limit 
of normal
Total protein
Blood Urea Nitrogen
All laboratory  samples will be collected as per Section 6.[ADDRESS_986047]:   MK-8616 47
Protocol/Amendment No.: 146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
ConfidentialPregnancy T ests [IP_ADDRESS]
Female subjects of child -bearing potential are required to have a negative pregnancy  test 
within [ADDRESS_986048] (provided by [CONTACT_35970]) or a serum β-human chorionic gonadotropin
pregnancy  test if this is part of the irstandard of care process (results analyzed at a local lab) .
If Visit [ADDRESS_986049] may be performed locally . Results (negative 
for pregnancy ) must be received b y site staff before the subject is given stu dy medication.
If serum pregnancy  is positive, the subject is to be discontinued from the trial.
Pharmacokinetic Evaluations [IP_ADDRESS]
Pharmacokinetic samples will be drawn at the following time points : 
Prior to administration of NMBA
At2, 5, 15, 60, and 120 minut esfollowing administration of sugammadex or 
neostigmine
At 4-6hours following administration of sugammadex or neostigmine 
At 10 -12 hours following administration of sugammadex or neostigmine*
*Note that depending on length of hospi[INVESTIGATOR_4408], the 10-12 hour samples may not be 
drawn; however, if the subject remains hospi[INVESTIGATOR_721944] 10-12 hour sample. For all subjects, blood samples for PK are to be 
drawn in the same arm, distal and upstream from where the study medication 
(sugammadex or neostigmine) is administered or in another location to ensure the 
study  medication has passed through the heart and arteries before reaching the sample 
vein.
[IP_ADDRESS].1 Blood Collection for Plasma MK-8616
Sample collection, storage ,and shipment instructions for plasma samples will be provided in 
theoperations/laboratory manual. 
Future Biomedical Research Sample s [IP_ADDRESS]
The following specimens are to be obtained as part of Future Biomedical Research:
DNA for future research 
  04YY9X 
  05C8LJ
Product:   MK-8616 48
Protocol/Amendment No.: 146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
ConfidentialOther Procedures 7.1.4
Withdrawal/Discontinuation [IP_ADDRESS]
Once a subject receives study  medication at Visit 2, all applicable procedures at subsequent 
visits should be performed as per stud y flow chart.
Any adverse events which are present at the time of withdrawal should be followed in
accordance with the safety  requirements outlined in Section 7.2 -Assessing and Recording 
Adverse Events.
[IP_ADDRESS].[ADDRESS_986050] the Sponsor 
using the designated mailbox ([EMAIL_1250]).  Subsequently , 
the subject's consent for Future Biomedical Research will be withdrawn.  A letter will be sent 
from the Sponsor to the investigator confirming the withdrawal. It is the responsibility  of the 
investigator to inform the subject of completion of withdrawal.  Any analy ses in progress at 
the time of request for withdrawal or alread y performed prior to the request being received 
by [CONTACT_90070].  
No new analy ses would be generated after the request is received.
In the event that the medical records for the main trial are no longer available (e.g., if the 
investigator is no longer required by [CONTACT_75357]) or 
the specimens have been completely  anonymized, there will no longer be a link between the 
subject’s personal information and their specimens.  In this situation, the request for 
specimen withdrawal cannot be processed .
[IP_ADDRESS].[ADDRESS_986051] fails to complete a required study  visit (e.g., follow -up safety  contact ) and/or if 
the site is unable to contact [CONTACT_423], the following procedures are to be performed :
The site must attempt to contact [CONTACT_75359].  
The investigator or designee must make every  effort to regain contact [CONTACT_14599] (e.g.,phone calls and/or a certified letter to the subject’s last known 
mailing address or locally  equivalent methods). These contact [CONTACT_225961]’s medical record.
Note:  A  s ubject is not considered lost to follow up until the last scheduled visit for the 
individual subject.  The amount of missing data for the subject will be managed via the pre-
specified data handling and anal ysis guide lines . 
  04YY9X 
  05C8LJ
Product:   MK-8616 49
Protocol/Amendment No.: 146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
Confidential7.[IP_ADDRESS] Subject Blinding/Unblinding
When the investigator or delegate needs to identify  the drug used by  a subject and the dosage 
administered in case of emergency  e.g., the occurrence of serious adverse experiences, he/she 
will contact [CONTACT_721978] a request for 
emergency  unblinding.  As requested by [CONTACT_721979]/her promptly  and report unblinding 
to the sponsor.  Prior tocontact[CONTACT_721980] a subject’s treatment assignment, the investigator or delegate must enter the 
intensity of the adverse experiences observed, the relation to study  drug, the reason thereof, 
etc., in the medical chart etc. Subjects whose treatment assignment has been unblinded by [CONTACT_1275]/delegate and/or non-study  treating physician must be discontinued from study  
drug, but should continue to be monitored in the trial.
Additionally , the investi gator must go into the IVRS system and perform the unblind in the 
IVRS system to update drug disposition.  In the event that the emergency  unblinding call 
center is not available for a given site in this trial, IVRS/I WRS should be used for emergency 
unblin ding in the event that this is required for subject safet y.
Treatment/Vaccine identification information is to be unmasked ONLY if necessary  for the 
welfare of the subject.  Every  effort should be made not to unbl ind the subject .
In the event that unblinding has occurred, the circumstances around the unblinding (e.g., 
date, reason and person performing the unblinding ) must be documented promptly , and the 
Sponsor Clinical Director notified as soon as possible. Only  the principal investigator [INVESTIGATOR_721945]’s code should be unblinded. Other t rial site personnel and 
Sponsor personnel directly  associated with the conduct of the trial should not be unblinded.
Subjects whose treatment assignment has been unblinded by [CONTACT_20616] r/delegate and/or 
non-study  treating physician must be discontinued from study  drug, but should continue to 
be monitored in the trial .
Calibration of Equipment [IP_ADDRESS]
The investigator or qualified designee has the responsibility  to ensure that any  device or 
instrument used for a clinical evaluation/test during a clinical study that provides information 
about inclusion/exclusion criteria and/or safety or efficacy  parameters shall be suitably  
calibrated and/or maintained to ensure that the data obtained is reliable and/or reproducible. 
Documentation of equipment calibration must be retained as source documentation at the 
study  site.
Visit Requirements 7.1.5
Visit requirements are outlined in Section 6 .0-Trial Flow Chart.   Specific procedure -related 
details are provide d above in Section 7.1 -Trial Procedures.
Screening (V1) [IP_ADDRESS]
Potential subjects will be evaluated to determine ifthey fulfill the entry  requirements as set 
forth in Section 5.1. Screening procedures may be repeated after consultation with the 
Sponsor.  
  04YY9X 
  05C8LJ
Product:   MK-8616 50
Protocol/Amendment No.: 146-[ADDRESS_986052] .
Peri-anesthetic Visit (V2) [IP_ADDRESS]
The following procedures will be followed during t he Peri-anesthetic visit:
1.Confirm the subject still meets inclusion/exclusion criteria 
2.Measure subject weight
3.Randomize the subject using IVRS.  Trial treatment should begin within 1 day of 
randomization.
a)Randomization 1 day before surgery (i.e., Visit 2 performed across 2 days)
In certain situations (e.g., if surgery  is scheduled for earl y morning), r andomization in 
IVRS may occur 1 day in advance of the scheduled surgery  only if the following 
procedures are completed prior to calling into IRT for randomization:
1.Confirm the subject meets inclusion/exclusion crite ria (including recalculation 
ofBMI using new weight measurement)
2.Take subject weight and recalculate BMI
If procedures above cannot be completed prior to randomizing the subject in IVRS, 
then randomization in I VRS cannot occur 1 day  in advance of the surgery .
*Visit 1 (V1) and Visit 2 (V2) should be conducted on separate days however in certain 
situat ions this may not be possible. For these exceptions, V1 and V2 may be conducted 
on the same day. Refer to guidance below.  
b)*V1 and V2: both visits performed in full on the same day
If V1 and V2 are conducted on the same day (including surgery ), the following 
procedures need only  be done once:
1.Inclusion/exclusion criteria review 
2.Concomitant medi cation review
3.Weight measurement and BMI calculation
All other protocol procedures (e.g., vital signs, safet y labs) must be conducted as 
indicated in the trial flow chart (Section 6.0) and as outlined in Section [IP_ADDRESS].
c)*V1 and V2: part of Visit 2 perform ed same day as V1 but surgery is scheduled 
for the next day (i.e., Visit 2 performed across 2 days)
If V1 and part of V2 are conducted on the same day (not including surgery ), the 
following procedures should be conducted prior to calling into IRT and only need to 
be done once.
1.Inclusion/exclusion criteria review 
2.Concomitant medication review
3.Weight measurement and BMI calculation 
  04YY9X 
  05C8LJ
Product:   MK - 8616 51
Protocol/Amendment No.: 146-01 
MK-8616-146-01 Final Protocol 5-Jul- 2018
ConfidentialAll other protocol procedures (e.g., vital signs, safet y labs) must be conducted as 
indicated in the trial flow chart (Section 6.0) and as outlined as outlined in Section 
[IP_ADDRESS].
d)If surgery is postponed more than 1day after randomization in IVRS :
Sites must contact [CONTACT_570755] a subject‘s surgery  is postponed for more than 
one day from the date the subject is randomized in IVRS (e.g., surgery  postponed 
due to subject illness).
Trial status of subjects in these situations will be handled on a case by [CONTACT_721981].
4.Pharmacist (or delegate) prepares study  medication (refer to Study  Drug Manual for 
details)
5.Insert an IV cannula for the administration of anesthetic drugs, NMBA , and study 
medication .
6.A second IV with flush will be inserted distally  and upstream in the same arm or from 
another location to allow collection ofblood samples for safet y and PK analy sesat 
predefined time points.
Administration of anesthesia: 
7.Anesthesia will be induced and maintained according to the need of the subject. Note:  
All drugs, date of administration, and actual doses given to the subject will need to be 
recor ded throughout the Peri-anesthetic visit and transferred to Sponsor database as 
required.
TOF -Watch SX®set-up, and before administration of the NMBA:
8.The TOF -Watch SX®accessories (transducers and electrodes) and/or device can be 
affixed prior to administration of anesthesia or after induction of anesthesia but prior to 
administration of NMBA.
9.Affix the TOF -Watch SX®and accessories (transducers and electrodes) accordin g to the 
Neuromuscular Transmission Monitoring Guidelines (provided separately ) to the arm 
contralateral to the arm used for study  medication administration or blood draws. Check 
the equipment, stabilize, and calibrate. In the event that TOF -Watch SX®data become 
unavailable due to device malfunction follow the general guidance provided in Section 
[IP_ADDRESS] Neuromuscular Monitoring.
10.Vital signs (per protocol) will be recorded
11.A baseline blood sample for safet y and PK analy sis will be obtained and sent to the 
central lab vendor .
12. A blood sample will be collected for future biomedical research (if consent obtained). 
  04YY9X 
  05C8LJ
Product:   MK - 8616 52
Protocol/Amendment No.: 146-01 
MK-8616-146-01 Final Protocol 5-Jul- 2018
ConfidentialNeuromuscular m onitoring : 
13.Neuromuscular monitoring will start before the administration of NMBA and recordin g 
will continue until the end of anest hesia. The laptop time (that is recorded in the TOF -
Watch SX®files) will be recorded for accounting with all trial-related assessments, such 
as administration of trial medication and blood sampling .  
Administration of NMBA until administration of study  medication:
14. Administer NMBA for intubation .Only  one NMBA should be used for the entire 
duration of surgery .  The NMBA used during surgery  should be the NMBA noted in the 
IVRS .
15.Additional doses of NMBA will be administered as clinicall y required for the duration of 
the surgery to maintain depth of block, as determined by [CONTACT_721982] .  Fluctuations in depth of block are expected as matter of course to 
accommodate of the needs of surgical procedures, however additional doses of NMBA
should be administered as clinicall y necessary  for the duration of the surgery  fortarget 
maintenance of the assigned depth of block .
16.Monitor the subject with the TOF -Watch SX®and record all activities ( e.g., 
administration of additional medicat ions, time of blood samples ) on the laptop during the 
entire duration of the surgery . 
17.Vital signs (per protocol) will be recorded .
18.Monitor and record a core body  temperature , after the last dose of NMBA is 
administered ,and at the time depth of block is assessed prior to administration of 
sugammadex or neostigmine.
From administration of study  medication (sugammadex or neostigmine) until the end of 
anesthesia :
19.For subject s randomized to moderate block: after last dose ofadministered NMBA and 
within 2 minutes of reappearance of T2, study  medication (sugammadex or neostigmine) 
will be administered.
20.For subjects randomized to deep block: after last dose of administered NMBA and within 
2 minutes of detection of a target of 1-2 PTC with a range of 1-5 PTC andTOF Count of 
0, study  medication (sugammadex) will be administered
.  
21.Study  staff should NOT record ‘sugammadex ’or ‘neostigmine ’ for annotation of study  
medication administration. To maintain blinding in the anesthetic chart, only indicate 
‘study  medication’ or ‘SM’ in the place of sugammadex or neostigmine. 
22.Continuous ECG monitoring: at least [ADDRESS_986053]:   MK-8616 53
Protocol/Amendment No.: 146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
Confidential23.The following additional study  procedur es should be done on the following schedule:
Time After 
Study 
Medication2 
min5 min10 
min15 
min30 
min45 min60 
min120 
min4-6 hr 10-12 hr
Vital Signs X X X X X X
Blood 
Samples for 
PK analysisX X X X X X X
Blood 
Samples for 
Safety LabsX
24.Continue neuromuscular monitoring until the recovery  of the TOF ratio ≥ 0.9; if TOF 
>=0.9 not reached, then monitoring should continue a minimum of 30 minutes after the 
administration of study medication. This enables the observation of recurrence of 
residual block should this occur.
25.Adverse event (s) and concomitant medication(s) will be recorded .
Post-Anesthetic Visit (V3) [IP_ADDRESS]
Visit [ADDRESS_986054] 4 hours following study  medication administration up to 
a maximum of 36 hours after study  medication administration (or before discharge, 
whichever is earlier) (see Flowchart, Section 6.0) .
The BSA will review the subject’s medical records in order to properl y assess the subject at 
this visit with the following exceptions: The drug preparation records, depth of 
neuromuscular block, study  medication given, and TOF -Watch SX®traces .
Follow -upSafety Contact (V4) [IP_ADDRESS]
Approximately  [ADDRESS_986055] study  medication administration ,subjects will be contact[CONTACT_721983] (or in person if the subject is still in the hospi[INVESTIGATOR_307]) .
New and ongoing AEs and concomitant medication (s)should be assessed and reported in the 
database. 
Assessing and Recording Adverse Events and Pati ent/Device Events 7.[ADDRESS_986056] a causal relationship with this treatment. An adverse event can therefore be any 
unfavourable and unintended sign (including an abnormal laboratory  finding, for example), 
symptom, or disease temporally  associated with the use of a medicinal product or protocol -
specified procedure, whether or not consi dered related to the medicinal product or protocol -
specified procedure.  Any worsening (i.e., any clinically  significant adverse change in 
frequency  and/or intensity ) of a preexisting condition that is temporally  associated with the 
use of the Sponsor’s pr oduct, is also an adverse event. 
  04YY9X 
  05C8LJ
Product:   MK - 8616 54
Protocol/Amendment No.: 146-01 
MK-8616-146-01 Final Protocol 5-Jul- 2018
ConfidentialChanges resulting from normal growth and development that do not vary significantl y in 
frequency  or severit y from expected levels are not to be considered adverse events.  
Examples of this may include, but are not limited to, teething, typi[INVESTIGATOR_26336] a phy siologically  appropriate time.
Sponsor's product includes any pharmaceutical product, biological product, device, 
diagnostic agent or protocol -specified procedure, whether investigational (including placebo 
or active comparator medication) or marketed, manufactured by, licensed by, provided by [CONTACT_75365].
Adverse events may occur during clinical trials, or as prescribed in clinical practice, from 
overdose (whether accidental or intentional), from abuse and from withdrawal.
All adverse events that occur after the consent form is signed but before treatment 
allocation/ randomization must be reported by [CONTACT_105943], or are the result of a protocol- specified intervention, including but 
not limited to washout or discontinuation of usual therap y, diet, placebo treatment or a 
procedure. From the time of treatment allocation /randomization through [ADDRESS_986057] be reported by [CONTACT_093]. Such events 
will be recorded at each examination on the Adverse Event case report forms/worksheets.  
The reporting timeframe for adver se events meeting any serious criteria is described in 
section [IP_ADDRESS]. The investigator will make every attempt to follow all subjects with non-
serious adverse events for outcome.
Electronic reporting procedures can be found in the Electronic Data Capture (EDC )data 
entry  guidelines. Paper reporting procedures can be found in the Investigator Trial File 
Binder (or equivalent).
Device and/or patient events include all untoward events related to the use of the device or 
device -like features of a drug deliver y system. Device events include any malfunction or 
deterioration in the characteristics and/or performance of the device, as well as any 
inadequacy  in the labeling or the instructions for use, that led to or could have led to an 
untoward event for the user or any person. Patient events are adverse events experienced by 
[CONTACT_721984] -like features of a 
drug delivery  system.
From the time of allocation/ randomization through [ADDRESS_986058] be reported by  [CONTACT_093]. Such events will be recorded 
at each examination on the Adverse Event case report forms/worksheets. The reporting 
timeframe for events meeting any serious criteria is describe d in section [IP_ADDRESS]. The 
investigator will make every  attempt to follow all non-serious device or subject events for 
outcome.  
Electronic reporting procedures can be found in the Electronic Data Capture (EDC )data 
entry  guidelines. Paper reporting proced ures can be found in the Investigator Trial File 
Binder (or equivalent). 
  04YY9X 
  05C8LJ
Product:   MK-8616 55
Protocol/Amendment No.: 146-[ADDRESS_986059] may  provide feedback related to the device or device -
like features of a drug delivery  system.  This "customer feedback" is defined as a report that 
does not allege a product quality  complaint or defect and has no relevant safety 
information/untoward event associated with it (e.g., goodwill or courtesy  replacement, 
consumer preference or suggestion, remark which may suggest an improvement in the 
functionality or qualit y of a medical device or device -like features of a drug delivery  system).  
All reports of customer feedback must be reported to the Sponsor.  Sponsor Contact 
[CONTACT_721985] I nvestigator Trial File Binder (or equiv alent).
Definition of an Overdose for This Protocol and Reporting of Overdose to the 7.2.1
Sponsor
In this trial, an overdose of sugammadex is considered a dose ≥2Xthe intended dose to 
which the subject was randomized . In this trial, an overdose of neostigmine is any dose 
greater than 5.0 mg as indicated in the labeling of neostigmine . Anoverdose of 
glycop yrrolate is considered a dose of greater than 2.0 mg..
If an adverse event(s) is associated with (“results from”) the overdose of Sponsor's produ ct or 
vaccine, the adverse event(s) is reported as a non-serious adverse event, unless other serious
criteria are met.
If a dose of Sponsor's product or vaccine meeting the protocol definition of overdose is taken 
without any associated clinical symptoms or abnormal laboratory  results, the overdose is 
reported as a non-serious adverse event using the terminology  “accidental or intentional 
overdose without adverse effect.”
All reports of overdose with and without an adverse event must be reported by [CONTACT_23514] 24 hours to the Sponsor either by [CONTACT_26365]. Electronic 
reporting procedures can be found in the EDC data entry  guidelines. Paper reporting 
procedures can be found in the I nvestigator Trial File Binder (or equivalent) .
Repor ting of Pregnancy and Lactation to the Sponsor 7.2.[ADDRESS_986060] 
(spontaneousl y reported to the m) that occurs during the trial .
Pregnancies and lactations that occur after the consent form is signed but before treatment 
allocation/ randomization must be reported by [CONTACT_105943], or are the result of a protocol -specified intervention, including but 
not limited to washout or discontinuation of usual therap y, diet, placebo treatment or a 
procedure.  Pregnancies and lactations that occur from the time of treatment 
allocation/ randomization through 14 days following cessation of Sponsor’s product must be 
reported by [CONTACT_093].  All reported pregnancies  must be followed to the 
completion/termination of the pregnancy . Pregnancy  outcomes of spontaneous abortion, 
missed abortion, benign hydatidiform mole, blighted ovum, fetal death, intrauterine death, 
miscarriage and stillbirth must be reported as serious events (Important Med ical Events). If 
the pregnancy  continues to term, the outcome (health of infant) must also be reported. 
  04YY9X 
  05C8LJ
Product:   MK-8616 56
Protocol/Amendment No.: 146-[ADDRESS_986061] be reported within 24 hours to the Sponsor either by [CONTACT_90079]. Electronic reporting procedures can be found in the EDC data entry guidelines. Paper 
reporting procedures can be found in the Investigator Trial File Binder (or equivalent).
Immediate Reporting of Adverse Events and Incidents to the Sponsor 7.2.3
Serious Adverse Events and Incidents [IP_ADDRESS]
A serious adverse event is any adverse event occurring at any dose or during any use of 
Sponsor's product that:
●Results in death;
●Is life threatening;
●Results in persistent or significant disability /incapacity ;
●Results in or prolongs an existing inpatient hospi[INVESTIGATOR_059];
●Is a c ongenital anomal y/birth defect;
●Is an other important medical event .
Note: In addition to the above criteria, adverse events meeting either of the below criteria, 
although not serious per ICH definition, are reportable to the Sponsor in the same timeframe 
as SAEs to meet certain local requirements. 
●Is a cancer;
●Is associated with an overdose .
Refer to Table 4for additional details regarding each of the above criteria.
For the time period beginning when the consent form is signed until treatment 
allocation/ randomization, any serious adverse event, or follow up to a serious adverse event, 
including death due to any  cause, that occurs to any  subject must be reported within [ADDRESS_986062] to be excluded from the trial, or is the result of a 
protocol -specified intervention, including but not limited to washout or discontinuation of 
usual therap y, diet, placebo treatment or a procedure.
For the time period beginning at treatment allocation/ randomization through 14 days 
following cessation of treatment, any  serious adverse event, or follow up to a s erious adverse 
event, including death due to any  cause, whether or not related to the Sponsor's product, must 
be reported within 24 hours to the Sponsor either by [CONTACT_26365]. Electronic 
reporting procedures can be found in the EDC data entry guidelines. Paper reporting 
procedures can be found in the I nvestigator Trial File Binder (or equivalent).
Additionally , any serious adverse event, considered by [CONTACT_19427] a qualified 
physician to be related to the Sponsor's product that is brought to the attention of the 
investigator at any time outside of the time period specified in the previous paragraph also 
must be reported immediately  to the Sponsor.
All subjects with serious adverse events must be followed up for outcome.
An incident is any malfunction or deterioration in the characteristics and/or performance of 
the device, as well as any inadequacy  in the labeling or the instructions for use that, directl y 
or indirectl y, led to or could have led to, the death of a subject or user, or of other persons, or 
to a serious deterioration in their state of health. 
  04YY9X 
  05C8LJ
Product:   MK-8616 57
Protocol/Amendment No.: 146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
ConfidentialA serious deterioration in the state of health can include:
Life- threatening illness, even if temporary  in nature;
Permanent impairment of a body  function or permanent damage to a body  structure;
Any indirect harm as a consequence of an incorrect diagnostic or IVD test results 
when used within instructions for use;
Fetal distress, fetal death or an y congenital abnormalities or birth defects;
Condition necessitating medical or surgic al intervention, including hospi[INVESTIGATOR_721946];
Cases that are considered medically  significant
For the time period beginning at treatment allocation/ randomization through [ADDRESS_986063] be reported within 24 hours to the Sponsor either by [CONTACT_26366].   Electronic reporting procedures can be found in the EDC data entry 
guidelines. Paper reporting procedures can be found in the Investigator Trial File Binder (or 
equivalent).
Additionally , any incident considered by [CONTACT_19427] a qualified physician to be 
related to the Sponsor's product that is brought to the attention of the investigator at any time 
outside of the time period specified above also must be reported immediately  to the Sponsor.
All subjects involved with incidents must be followed up for outcome.
Events of Clinical Interest [IP_ADDRESS]
Selected non-seriou s and serious adverse events are also known as Events of Clinical I nterest 
(ECI)  and must be reported to the Sponsor.
For the time period beginning when the consent form is signed until treatment 
allocation/ randomization, any  ECI, or follow up to an ECI , that occurs to any  subject must be 
reported within [ADDRESS_986064] to be excluded from the trial, 
or is the result of a protocol -specified intervention, including but not limited to washout or 
discontinuation of usual thera py, diet, placebo treatment or a procedure.
For the time period beginning at treatment allocation/ randomization through 14days 
following cessation of treatment, any ECI, or follow up to an ECI, whether or not related to 
the Sponsor’s product, must be reported within 24 hours to the Sponsor, either by [CONTACT_26366].  Electronic reporting procedures can be found in the EDC data entry 
guidelines.  Paper reporting procedures can be found in the Investigator Trial File Binder (or 
equivalent). 
  04YY9X 
  05C8LJ
Product:   MK-8616 58
Protocol/Amendment No.: 146-[ADDRESS_986065] for this trial include:
1. an elevated AST or ALT lab value that is greater than or equal to 3X the upper limit of 
normal and an elevated total bilirubin lab value that is greater than or equal to 2X the 
upper limit of normal and, at the same time, an alkaline phosphatase lab value that is less 
than 2X the upper limit of normal, as determined by [CONTACT_398841] -specified laboratory  
testing or un scheduled laboratory  testing.*
*Note:  These criteria are based upon available regulatory guidance documents. The 
purpose of the criteria is to specify  a threshold of abnormal hepatic tests that may  require 
an additional evaluation for an underl ying etiology. The trial site guidance for assessment 
and follow up of these criteria can be found in the Investigator Trial File Binder (or 
equivalent).
2. Clinically  relevant arrhy thmias, inclusive ofclinically  relevant sinus brady cardia and 
clinically  relevant sinus tachy cardia
Clinically relevant sinus bradycardia isdefined as any brady cardia event
necessitating intervention, as determined b y investigator judgment . 
Clinically relevant sinus tachycardia isdefined as an y tachycardia event
necessitat ing intervention , as determined b y investigator judgment . 
Other clinically relevant cardiac arrhythmia isdefined as any arrhythmia 
event necessitating intervention ,as determined by [CONTACT_134970] (i.e.,
new or worsening atrial fibrillation, atrial tachy cardia, ventricular tachy cardia, 
or ventricular fibrillation, etc) .
3. Hypersensitivit y and/oranaph ylaxis
Hypersensitivity: The term hypersensitivity describes objectivel y 
reproducible sy mptoms and signs of allergic disease initia ted by [CONTACT_27178] a 
defined stimulus at a dose tolerated by [CONTACT_721986]. Refer to the ECI 
Guidance document (or equivalent) for more information .
Anaphylaxis: The term anaph ylaxis is an umbrella term for a serious, life-
threatening generalized or systemic hypersensitivity reaction that is rapid in 
onset. For the purpose of this study , adjudication of potential cases of 
anaph ylaxis is defined by [CONTACT_721987]. [5].
Evaluating Adverse Events 7.2.[ADDRESS_986066] to 
the elements outlined in Table 4. The investigator’s assessment of causality  is required for 
each adverse event.  Refer to Table [ADDRESS_986067]:   MK - 8616 59
Protocol/Amendment No.: 146-01 
MK-8616-146-01 Final Protocol 5-Jul- 2018
ConfidentialTable 4 Evaluating Adverse Events
Maximum Mild awareness of sign or symptom, but easily tolerated  (for pediatric trials, awareness of symptom, but easily tolerated)
Intensity Moderate discomfort enough to cause interference with usual activity (for pediatric trials, definitely acting like something is wrong)
Severe incapacitating with inability to work or do usual activity (for pediatric trials, extremely distressed or unable to do usual activities)
Seriousness A serious adverse event (AE) is any adverse event occurring at any dose or during any use of Sponsor's product that:
†Results in death ; or
†Is life threatening; or places the subject, in the view of the investigator, at immediate risk of death from the event as it occurred [Note: This does not include an 
adverse event  that, had it occurred in a more severe form, might have caused death.]; or
†Results in a persistent or significant di sability/incapacity (substantial disruption of one’s ability to conduct normal life functions); or
†Results in or prolongs an existing inpatient hospi[INVESTIGATOR_059] (hospi[INVESTIGATOR_19357], regardless of length of stay, even if the 
hospi[INVESTIGATOR_2138] a precautionary measure for continued observation.   (Note: Hospi[INVESTIGATOR_19358] a pre-existing condition that has not 
worsened is not a serious adverse event.  A pre- existing condition is a clinical con dition that is diagnosed prior to the use of a [COMPANY_006] product and is documented in the 
patient’s medical history. ); or
†Is a congenital anomaly/birth defect  ( in offspring of subject taking the product regardless of time to diagnosis); or
Is a cancer (although not serious per IC Hdefinition, is reportable to the Sponsor within 24 hours to meet certain local requirements) ;or
Overdose, although not serious per ICH definition, whether accidental or intentional, with or without an accompanying adverse event/serious adverse event, is 
reportable to the Sponsor within [ADDRESS_986068] and may require medical or surgical interventio n to prevent one of the outcomes listed 
previously (designated above by a †).
Duration Record the start and stop dates of the adverse event.  If less than 1 day, indicate the appropriate length of time and units
Action taken Did the adverse event cause the Sponsor's product to be discontinued?
Relationship to 
Sponsor's 
ProductDid the Sponsor's product cause the adverse event?   The determination of the likelihood that the Sponsor's product caused the adverse event will be provided by [CONTACT_26368] a qualified physician.  The investigator’s signed/dated initials on the source document or worksheet that supports the causality noted on the AE 
form, ensures that a medically qualified assessment of causality was done.  This initialed document must be retained for the required regulatory time frame.  The 
criteria below are intended as reference guidelines to assist the investigator in assessing the likelihood of a relationship between the test drug and the adverse event 
based upon the available information
The following components are to be used to assess the relationship between the Sponsor's product and th e AE ; the greater the correlation with the components 
and their respective elements (in number and/or intensity), the more likely the Sponsor's product caused the adverse event:
Exposure Is there evidence that the subject was actually exposed to the Sponsor's product such as:  reliable history, acceptable compliance assessment (pi[INVESTIGATOR_9650], diary, etc.), expected pharmacologic effect, or measurement of drug/metabolite in bodily specimen?
Time Course Did the AE follow in a reasonable temporal sequence from administration of the Sponsor's product? 
Is the time of onset of the AE compatible with a drug -induced effect (applies to trials with investigational medicinal product)?
Likely Cause Is the AE notreasonably explained by [CONTACT_26369], other drug(s)/vaccine(s), or other host or environmental
factors 
  04YY9X 
  05C8LJ
Product:   MK - 8616 60
Protocol/Amendment No.: 146-01 
MK-8616-146-01 Final Protocol 5-Jul- 2018
ConfidentialRelationship The following components are to be used to assess the relationship between the Sponsor's product and the AE:  (continued)
to Sponsor's 
Product
(continued) Dechallenge Was the Sponsor's product discontinued or dose/exposure/frequency reduced?
      If yes, did the AE resolve or improve?
           If yes, this is a positive dechallenge.    If no, this is a n egative dechallenge.
(Note:  This criterion is not applicable if:  (1) the AE resulted in death or permanent disability; (2) the AE resolved/impro ved despi[INVESTIGATOR_90044]'s product; (3) the trial is a single -dose drug trial); or (4) Sponsor' s product(s) is/are only used one time.)
Rechallenge Was the subject re- exposed to the Sponsor's product in this trial?
      If yes, did the AE recur or worsen?
          If yes, this is a positive rechallenge.    If no, this is a negative rechallenge.
(Note:  This criterion is not applicable if:  (1) the initial AE resulted in death or permanent disability, or (2) the trial is a single -dose drug trial); 
or (3) Sponsor's product(s) is/are used only one time.)
NOTE:  IF A RECHALLENGE IS PLANNED FOR AN ADVERSE EVENT WHICH WAS SERIOUS AND WHICH MAY HAVE BEEN 
CAUSED BY [CONTACT_26370]'S PRODUCT, OR IF RE -EXPOSURE TO THE SPONSOR'S PRODUCT POSES ADDITIONAL POTENTIAL 
SIGNIFICANT RISK TO THE SUBJECT THEN THE RECHALLENGE MUST BE APPROVED IN ADVANCE BY [CONTACT_721988]/INDEPENDENT ETHICS COMMITTEE.
Consistency 
with Trial 
Treatment 
ProfileIs the clinical/pathological presentation of the AE consistent with previous knowledge regarding the Sponsor's product or dru g class 
pharmacology or toxicology?
The assessment of relationship will be reported on the case report forms /worksheets by [CONTACT_19427] a qualified ph ysician according to his/her best clinical judgment, including 
consideration of the above elements.
Record one of the following : Use the following scale of criteria as guidance (not all criteria must be present to be indicative of a Sponsor's product rel ationship).
Yes, there is a reasonable 
possibility of Sponsor's product 
relationship.There is evidence of exposure to the Sponsor's product.  The temporal sequence of the AE onset relative to the administration of the Sponsor's 
product is reasonable.  The AE is more likely explained by [CONTACT_1034]'s product than by [CONTACT_5748]. 
No, the re is not a reasonable 
possibility of Sponsor's product 
relationshipSubject did not receive the Sponsor's product OR temporal sequence of the AE onset relative to administration of the Sponsor' s product is not 
reasonable OR the AE is more likely explained by [CONTACT_26372]’s product .  (Also entered for a subject with overdose without 
an associated AE.) 
  04YY9X 
  05C8LJ
Product:   MK-8616 61
Protocol/Amendment No.:   146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
ConfidentialSponsor Responsibility for Reporting Adverse Events and Patient/Device Events 7.2.5
and Incidents
AllAdverse Events and Patient/Device Events and Incidents will be reported to regulatory  
authorities, IRB/IECs and investigators in accordance with all applicable global laws and 
regulations , i.e., per ICH Topic E6 (R1) Guidelines for Good Clinical Practice .
TRIAL GOVERNANCE AND OVERSIGHT 7.3
Data Monitoring Committee 7.3.1
Astanding internal Data Monitoring Committee (siDMC )consisting of Internal Sponsor 
personnel, unblinded to treatment groups for the purposes of reviewing analyses, will be 
responsible for reviewing the results of the PK -only interim analy sis. 
The siDMC will review the results of the planned IA andmake recommendations regarding
the need tostudy the 16 mg/kg dose of sugammadex. The siDMC will not be provided any 
safet y or efficacy  data and will operate independently  of the external Clinical Adjudication 
and Neuromuscular Monitoring Adjudication Committees .
Clinical Adjudication Committee 7.3.2
A Clinical Adjudication Committee (CAC) will evaluate the following events for the 
purposes of confirming them according to the criteria in Section 8.0 –Statistical Analy sis 
Plan, as well as evaluating the presence of co nfounding factors.
This external committee of independent consultants will assess the following e vents:
Hypersensitivity  and/or anaphy laxis
The BSA and/or Principal Investigator (or delegate) will identify  events to be adjudicated. In 
addition, the Sponsor will periodically  review the blinded clinical database in order to 
identify  events that may meet criteria for adjudication. Upon identification of such an event, 
the Sponsor may query  the site for additional information.
All personnel involved in the ad judication process will remain blinded to treatment allocation 
throughout the trial.
Neuromuscular Monitoring Adjudication Committee [IP_ADDRESS]
An independent vendor will review all TOF traces to assess overall data quality  and 
acceptability  of investigative site TOF -operator’s interpretation of the efficacy  variables and 
adherence to NMTM guidelines. In instances where resolution between the vendor and site 
personnel regarding the interpretation of trace output is needed , traces or data points will be 
reviewed by [CONTACT_721989] (NMAC).
The NMAC will assess trace data objectivel y, independentl y, and without knowledge of 
subject treatment or condition, and either confirm the acceptability  of investigative site TOF -
operator’s interpretation or provide a separate interpretation to be used as part of the efficacy 
analysis. 
  04YY9X 
  05C8LJ
Product:   MK-8616 62
Protocol/Amendment No.:   146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
Confidential8.0STATISTICAL ANALYSIS PLAN
This section outlines the statistical analysis strategy  and procedures for the study .  If, after 
the study  has begun, but prior to any unblinding, changes made to primary  and/or key 
secondary  hypotheses, orthe statistical methods related to those hypotheses, then the 
protocol will be amended (consistent with ICH Guideline E-9).  Changes to exploratory  or 
other non-confirmatory  analyses made after the protocol has been finalized, but prior to 
unblinding, will be documented in a supplemental Statistical Analysis Plan(sSAP) and 
referenced in the clinical study  report (CSR) for the study .  Post hoc exploratory  analyses 
will be clearl y identified in the CSR.
Statistical Analysis Plan Summary 8.1
Key elements of the statistical analy sis plan are summarized below; the comprehensive plan 
is provided in Sections 8.2-8.12.  
Study Design Overview A random ized, active comparator -controlled trial evaluating the 
efficacy and safety of sugammadex when used to reverse 
neuromuscular blockade induce d by [CONTACT_721990].
Treatm entAssignment Subjects will be stratified by [CONTACT_721991] (moderate or deep) and reversal agent in a 1:1:1:1:1 ratio as 
follows:
1.Moderate block and reversal with sugammadex 2 mg/kg, based on 
ABW
2.Moderate block and reversal with sugammadex 2 mg/kg, based on 
IBW
3.Moderate block and reversal with neostigmine(0.05 mg/kg up to 5 
mg) + glycopy rrolate (10 µg/kg up to 1 mg maximum dose) based 
on ABW
4.Deep block and reversal with sugammadex 4mg/kg, based on 
ABW
5.Deep block and reversal with sugammadex 4 mg/kg, based on 
IBW
Analysis Populations Efficacy: All Subjects Treated (AST)
Safety: All Subjects as Treated (ASaT)
Prim ary Endpoint(s) The tim e to recovery to a TOF ratio of ≥0.9 for a comparison of ABW 
and IBW dosing of sugammadex pooled across depth of block and 
NMBA
Key Secondary Endpoint (s) Distribution of time to recovery to a TOF ratio of ≥0.7, ≥0.8 and ≥0.9
as well asthe proportions of subjects with prolonged recovery (>10 
minutes) pooled across depth of block and NMBA .
Statistical Methods for Key 
Efficacy AnalysesThe primary hypothesis will evaluate the efficacy of sugammadex 
when dosed according to ABW as compared with IBW on time to 
recovery to a TOF ratio of ≥ 0.9using a stratified log-rank test
(adjusted for the depth of block and NMBA ). Event rates over time 
will be estimated within each treatment group using the Kaplan -Meier 
method.  
  04YY9X 
  05C8LJ
Product:   MK-8616 63
Protocol/Amendment No.:   146-[ADDRESS_986069] to inferential testing for statistical significance with 
95% confidence intervals for betw een-group comparisons. Tier 2 
parameters will be assessed via point estimates with 95% confidence 
intervals provided for between- group comparisons ; only point 
estimates by [CONTACT_113825] 3 safety 
parameters.
Interim Analyses A pharm acokinetic (PK) only IAwill be conducted in this study when 
approximately 64 evaluable subjects treated with sugammadex
(approximately 16 subjects per treatment dose [2 mg/kg and 4 mg/kg] 
and weight -based dosing [ABW and IBW] categories) have been 
enrolled, in order to examine the PK profile of sugammadex in the 
setting of morbid obesity. No unblinding of safety or efficac y will 
occur in support of this PK -only IA. 
Multiplicity No m ultiplicity adjustment is planned .
Sample Size and Power The total planned sample size is approximately 200 subjects. If 
subjects are equal lyallocat edin each NMBA strata, there wouldbe 
~100 subjects per NMBA with ~20 subjects in each of the 5 treatm ent 
arms. However, ifapproximately 30% of the total subjects (i.e., 60 
subjects) are enrolled inthe vecuronium stratum, there wouldbe~12 
subjects ineach of the 5 treatment groups in the vecuronium stratum.
Assuming the difference of median time-to-recovery in ABW and 
IBW groups is one minute based on the simulated data, a sample size 
of N ~ 80 per group (across both NMBA and depth of block) provides 
estimated pow er of >99% to detect a shift in time -to-recovery .
Responsibility for Analyses/In -House Blinding 8.2
The statistical analysis of the data obtained from this study  will be the responsibility  of the 
Clinical Biostatistics department of the Sponsor .
Sponsor study  team personnel will be blinded to study  medication assignments for 
randomized subjects, with the exception of designated Sponsor personnel (e.g., unblinded 
Clinical Research Associates [CRAs], the pharmacokineticist, statistician(s) not associated 
with the study  who will complete the PK IA and provide the data to the siDMC, and other 
designated individuals as required). The official final database will not be unblinded until 
medical/scientific review has been performed, protocol deviations have been identified, and 
data have b een declared final and complete.
The Clinical Biostatistics department will generate the randomized allocation schedule(s) for 
study  treatment assignment.  Randomization will be implemented using anIVRS.
Hypotheses/Estimation 8.3
Objectives and h ypotheses of the stud y are stated in Section 3 .0.
Analysis Endpoints 8.4
Efficacy  and safet y endpoints that will be evaluated for within -and/or between -treatment 
differences are listed below, followed by [CONTACT_296481]. 
  04YY9X 
  05C8LJ
Product:   MK-8616 64
Protocol/Amendment No.:   146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
ConfidentialEfficacy Endpoints 8.4.1
The primary  efficacy  endpoint is the time to recovery  to a TOF ratio of ≥0.9 for a comparison 
of ABW and IBW based dosing of sugammadex. See Section [IP_ADDRESS] for more details .
Secondary  efficacy  endpoints are:
Summary  statistics for the recovery times to TOFs of ≥0.7, ≥0.8 and ≥0.9 forABW 
and IBW dosing groups pooled across both the depth of block and NMBA
The proportion s of subjects with prolonged recovery  (>10 minutes) for ABW and 
IBW dosing gr ou
pspooled across both the depth of block and NMBA
Exploratory  efficacy  endpoint sare:
Summary  statistics for the recovery  times forsugammadex and neostigmine in the 
setting of moderate block pooled across NMBA
Summary  statistics for the recovery  times to TOFs of ≥0.7, ≥0.8 and ≥0.9 for ABW 
and IBW dosing groups separately  by [CONTACT_721992]
The proportions of subjects with prolonged recovery  (>10 minutes) for ABW and 
IBW dosing groups by [CONTACT_721993] b y NMBA.
Safety Endpoints 8.4.2
Safety  endpoints that will be evaluated in each dosing group are listed below. For safety 
analyses other than the primary  safety  endpoint (which includes events up to [ADDRESS_986070] 
administration of study  medication), the primary  approach to the summary  of AEs will 
include all events that occur up to 7days post administration of study medication.  A 
supplemental summary  of all AEs occurring up to [ADDRESS_986071] administration of study 
medication will also be included.
The primary  safet y endpoints are: 
Proportion of subjects with treatment emergent sinus brady cardia defined as a heart 
rate <60 bpm that has also decrease dmore than 20%,compared to the subject’s 
baseline heart rate value , sustained for at least 1minute after administration of study  
medication .
Proportion of subjects with treatment emergen tsinus tachy cardia defined as a heart 
rate ≥100 bpm that has also increase dmore than 20%,compared to the subject’s 
baseline heart rate value , sustained for at least 1minute after administration of study  
medication .
Proportion of subjects with other treatment emergent cardiac arrhythmias defined as 
new or worsening arrhythmias (e.g., atrial fibrillation, atrial tachy cardia, ventricular 
fibrillation, orventricular tachycardia ),sustained for at least 1minute after 
administration of study  medication . 
  04YY9X 
  05C8LJ
Product:   MK-8616 65
Protocol/Amendment No.:   146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
ConfidentialThe baseline heart rate for the primary  safety endpoints will be recorded approximately  five 
minutes before administration of study  medication (sugammadex or neostigmine) to 
determine events of treatment emergent sinus bradycardia , treatment emergent sinus
tachycardia , or other treatment emergent cardiac arrhythmias .In addition tothe primary 
safet y endpoints, 
Some supportive safet y endpoints considered as Tier 2endpoints are listed below:
Proportion of subjects with adjudicated hypersensitivity
Proporti on of subjects with adjudicated anaphy laxis
Proportion of subjects with at least one clinic ally relevant sinus bradycardia event
defined as any bradycardia event necessitating intervention, as determined by 
[CONTACT_134970]
Proportion of subjects with at least one clinic ally relevant sinus tachycardia event
defined as any tachy cardia event necessitating intervention, as determined by 
[CONTACT_134970]
Proportion of subjects with a least one other clinically  relevant cardiac arrhythmia 
defined as any other cardiac arrhythmia event necessitating intervention, as 
determined b y investigator judgment
In addition, proportion of subjects with any AE, serious AE, drug -related AE, serious and 
drug-related AE, discontinuation due to AE and specific AEs, SOCs, or PDLCs (incidence ≥4 
of subjects in one of the treatment group) will be considered as Tier [ADDRESS_986072]. Sugammadex 
pharmacokinetic parameters will be calculated using noncompartmental methods.  The 
apparent terminal rate constant (λ) will be estimated by [CONTACT_232287] -linear 
portion of the plasma concentration time profile; apparent terminal t½ will calculated as the 
quotient of ln(2) and λ. AUC to the last time point with a quantifiable plasma concentration 
(AUC0 -last) will be calculated using the linear trapezoidal method for ascending 
concentrations and the log trapezoidal method for descending concentrations up to the last 
quantifiable plasma concentration.  Total exposure (AUC0 -inf) will beestimated as the sum 
of AUC0 -last and the extrapolated area given by [CONTACT_721994] λ.  The maximum observed concentration (Cmax) will be obtained by 
[CONTACT_721995].  Mean residence time (MRT) of sugammadex in 
the systemic circulation following IV administration will be estimated. Tota l clearance 
(CL=Dose/ AUC0 -inf) and volume of distribution (Vd), defined as volume of distribution 
estimated at steady -state following a single IV dose adm inistration ( Vss=MRT x CL) and Vd 
during the terminal elimination phase (i.e. Dose/( AUC0 -infx λz) will be calculated. No 
value for AUC0 -∞, CL, λz, t1/2, Vz, MRT, Vss will be reported for concentration -time 
profiles where the terminal linear phase is not clearly  defined. 
  04YY9X 
  05C8LJ
Product:   MK-8616 66
Protocol/Amendment No.:   146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
ConfidentialAdditional pharmacokinetic anal yses may  be conducted if deemed appropriate.
Derivations of Efficacy /Pharmacokinetics Endpoints 8.4.[ADDRESS_986073] case scenario for neostigmine will be applied, consistent with the 
approach used in the adult program. For each of the two NMBAs, separately , the following 
procedure will be used:
If the time from the start of administration of study drug to recovery  of the TOF ratio to 0.9 is 
missing, there are three cases of particular importance for imputation purposes: 
1.Time to TOF ratio to 0.8 is available: 
Sugammadex group: first, for a ll subjects randomized to receive sugammadex and 
with times to recovery of the TOF ratio to 0.8 and 0.9 available, the difference 
between these two recovery  times will be calculated. Next, the 95th percentile 
(P95) of these differences will be added to the time to recovery  of the TOF ratio 
to 0.8 of the subjects with missing times to recovery  of the TOF ratio to 0.9. This 
will be used as the imputed missing time to recovery of the TOF ratio to 0.9.
Neostigmine group: same as for the sugammadex group but now only subjects 
randomized to receive neostigmine will be used, and the 5th percentile (P5) of the 
differences in time to recovery  of the TOF ratio to 0.8 and 0.9 will be calculated.
2.Time to TOF ratio to 0.7 is available, but the time to TOF ratio to 0.8 is missing: 
Sugammadex group: first for all subjects randomized to sugammadex and with 
times to recovery  of the TOF ratio to 0.7 and 0.9 available, the difference in time 
between these two recovery  times will be calculated. Next, the P95 of these 
differe nces will be added to the time to recovery  of the TOF ratio to 0.7. This 
will be used as imputation of the missing time to recovery of the TOF ratio to 0.9.
Neostigmine group: same as for sugammadex group but now only subjects 
randomized to receive neosti gmine will be used and the P5 of the differences in 
time to recovery  of the TOF ratio to 0.7 and 0.9 will be calculated. 
3.Times to TOF ratio to 0.7 and to 0.8 are both missing:
Sugammadex group: the P95 of the time to recovery  in all subjects randomized to 
sugammadex with an observed recovery  time of the TOF ratio to 0.9 will be 
imputed.
Neostigmine group: the P5 of the time to recovery in all subjects randomized to 
neostigmine with an observed recovery  time of the TOF ratio to 0.9 will be 
impu ted. 
A corresponding procedure will be followed for imputation of missing times from the start of 
administration of study drug to recovery  of the TOF ratio to 0.8 (secondary  efficacy  
variable). For imputation of missing times, P95 (sugammadex) or P5 (neostigmine) of the 
differences in time between recovery  of the TOF ratio to 0.[ADDRESS_986074]:   MK-8616 67
Protocol/Amendment No.:   146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
ConfidentialFor imputation of missing times from the start of administration of study  drug to recovery  of 
the TOF ratio to 0.7 (secondary  efficacy  variable), the P95 observed time for the subjects 
randomized to the sugammadex group will be imputed. For subjects randomized to the 
neostigmine group the P5 observed time will be imputed. Imputation of missing times of the 
primary  and secondary  efficacy  variables, however, s hould alway s result in a non -descending 
sequence of times to recovery  of the TOF ratios to 0.7, 0.8, and 0.9.
Analysis Populations   8.[ADDRESS_986075] sTreated (AST ) population will serve as the primary  population for the 
analysis of efficacy data in this study .  The AST population consists of all randomized
subjects who:
are dosed with both an NMBA and reversal agent ( study  treatment ),
have at least one post -randomization efficacy assessment. 
Subjects will be included in the treatment group to which they are randomized for the 
analysis of efficacy  data using the AST population .  Details on the approach to handling 
missing data are provided in Section 8.6.1 Statistical Methods.
Safety Analysis Population 8.5.2
The All Subjects asTreated (ASaT) population will be used for the analy sis of safet y data in 
this study .  The ASaT population consists of all randomized subjects who received at least 
one dose of study  treatment. Subjects will be included in the treatment group correspondi ng 
to the study  treatment they actuall y received for the analysis of safet y data using the ASaT 
population.  For most subjects ,this will be the treatment group to which they  are randomized.  
Subjects who take incorrect study  treatment will be included in the treatment group 
corresponding to the stud y treatment actually  received. 
At least one laboratory  or vital sign measurement obtained subsequent to at least one dose of 
study  treatment is required for inclusion in the analy sis of each specific parameter.   To assess 
change from baseline, a baseline measurement is also required.
Details on the approach to handling missing data for safet y analy ses are provided in Section 
8.6.[ADDRESS_986076]:   MK-8616 68
Protocol/Amendment No.:   146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
ConfidentialStatistical Methods 8.6
Statistical testing and inference for efficacy  and safet y analyses are described in 8.6.1 and 
8.6.2 respectivel y.  Efficacy  results that will be deemed to be statistically  significant after 
consideration of the Type I error control strategy are described in Section 8.8, Multiplicity . 
Nominal p-values will becomputed for other efficacy  analyses, but should be interpreted 
with caution ,due to potential issues of multiplicity , 
sample size, etc.  Unless otherwise 
stated, all statistical tests will be conducted at the α=0.05 (2 -sided) level.
Statistical Methods for Efficacy Analyses 8.6.1
This section describes the statistical methods that address the primary  and secondary 
objectives. Methods related to exploratory  objectives will be described in the supplemental 
SAP.
All efficacy  analy ses will be based on the All Subjects Treated population.
The primary  efficacy  endpoint is the time to recovery , defined as a TOF ratio (i.e. T4/T1
ratio) ≥0.[ADDRESS_986077] ics(mean, standard deviation, median, 
geometric mean and its 95% CI) will be provided, as well asthe proportions of subjects with 
prolonged time to recovery  (>10 minutes) by [CONTACT_6660] (pooled and separatel y by 
[CONTACT_721996]). In addition, the 95% confidence intervals for pairwise 
differences will be provided for time to recovery  and proportions (both overall and separately 
by [CONTACT_721996]).
Table [ADDRESS_986078]:   MK-8616 69
Protocol/Amendment No.:   146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
ConfidentialTable 5 Analy sis Strategy  for Key  Efficacy  Variables
Endpoint/Variable
(Description, Time Point)Primary vs. 
Supportive 
Approach†Statistical Method‡Analysis 
PopulationMissing Data 
Approach
Primary Endpoint/ Hypothesis
Time to recovery to a TOF ratio ≥ 
0.9for ABW and IBW dosing 
groups pooled across depth of 
block and NMBAP Stratified Log-rank test AST Censored
Secondary Endpoints
Distribution of time to recovery of 
TOFs of ≥0.7, ≥0.8 and ≥0.9S Descriptive statistics
(cumulative 
distribution plots, 
boxplots , mean, 
standard deviation, 
median,  geometric 
mean and its 95% CI )AST Explicit
Imputation
Distribution of t ime to recovery of 
TOFs of ≥0.7, ≥0.8 and ≥0.9for 
ABW and IBW dosing groups , 
pooled across depth of block and 
NMBAS Pairwise difference in 
geometric mean and 
95% CIAST Explicit 
Imputation
Proportion of subjects with 
prolonged time to recovery (> 10 
minutes) for ABW and IBW 
dosing groups, pooled across 
depth of block and NMBAS Pairwise difference in 
proportion and 95% CI 
using the stratified 
Miettinen and 
Nurminen methodAST Explicit 
Imputation
Distribution of t ime to recovery of 
TOFs of ≥0.7, ≥0.8 and ≥0.9for 
ABW and IBW dosing groups , 
separately by [CONTACT_721997] 
95% CIAST Explicit 
Imputation
Proportion of subjects with 
prolonged time to recovery (> 10 
minutes ) for ABW and IBW 
dosing groups, separately by 
[CONTACT_721998] 95% CI 
using the stratified 
Miettinen and 
Nurminen methodAST Explicit
Imputation
†P=Primary approach; S=Supportive approach.
Imputation approach described in Section 8.4.4.
‡ Statistical models are described in Section 8.6.1 .
Statistical Methods for Safety Analyses 8.6.2
All safet y anal yses will be based on the All Subjects as Treated population .
Safety  and tolerability  will be assessed by [CONTACT_14339] ,
including AEs, laboratory tests, and vital signs . 
The analysis of safet y results will follow a tiered approach (Table 6).  The tiers differ with 
respect to the analyses that will be performed.  Safety  parameters or adverse experiences of 
special interest that are identified a priori constitute “Tier 1” safet y endpoints that will be 
subject to inferential testing for statistical significance with p-values and 95% confidence 
intervals provided for between -group comparisons.  Other safet y parameters will be  
  04YY9X 
  05C8LJ
Product:   MK - 8616 70
Protocol/Amendment No.:   146-01 
MK-8616-146-01 Final Protocol 5-Jul- 2018
Confidentialconsidered Tier 2 or Tier 3.  Tier 2 parameters will be assessed via point estimates with 95% 
confidence intervals provided for between -group comparisons; only point estimates by 
[CONTACT_113825] 3 safety  parameters.
The incidence of safety parameters will be summarized by [CONTACT_721999] 5 dosing groups. Between -group comparisons will be made for each ABW 
and IBW dosing group of sugammadex and neostigmine pooled across NMBA ,as well as 
separately  by [CONTACT_722000] . The primary  safety endpoints, as well as other supportive safet y 
endpoints are considered Tier 1 events. Both Tier 1 and Tier 2 endpoints will be estimated 
with 95% confidence interval by [CONTACT_722001] -Pearson method [7]. P-
values (Tier 1 onl y) and 95% confidence interval (Tier 1 and Tier 2) will be provided for 
between -treatment differences using the stratified Miettinen andNurminen method [8]with 
NMBA as a stratification factor.
Adverse experiences (specific terms as well as System Organ Class terms) and predefined 
limits of change in laboratory andvital signs that are not pre-specified as Tier-[ADDRESS_986079] 4 subjects in any treatment group exhibit the 
event; all other AEs and predefined limits of change will belong to Tier 3.
The threshold of at least 4 events was chosen because the 95% CIfor the between- group 
difference in percent incidence will alway s include zero when treatment groups of equal size 
each have fewer than 4 events and thus would add little to the interpretation of potentially  
meaningful differences.  Because many 95% CIs may be provided without adjustment for 
multiplicity , the CIs should be regarded as a helpful descriptive measure to be used in 
revie w, not a formal method for assessing the statistical significance of the between- group 
differences in AE and predefined limits of change.
Continuous measures ,such as changes from baseline in laboratory  andvital signs that are not 
pre-specified as Tier-[ADDRESS_986080]:   MK-8616 71
Protocol/Amendment No.:   146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
ConfidentialTable 6 Analy sis Strategy for Safety  Parameters
Safety Tier Safety Endpointap-Value95% CI for 
Treatment 
ComparisonDescriptive 
Statistics
Tier 1 Treatment emergent sinus bradycardia X X X
Treatment emergent sinus tachycardia X X X
Other treatment emergent cardiac arrhythmias X X X
Tier 2 Adjudicated hypersensitivity X X
Adjudicated anaphylaxis X X
Clinically relevant sinus bradycardia X X
Clinically relevant sinus tachycardia
Other clinically relevant cardiac arrhythmiaX
XX
X
Any AE X X
Any serious AE X X
Any drug -related AE X X
Any serious and drug -related AE X X
Discontinuation due to AE X X
Specific AEs, SOCs, or PDLCsb(incidence ≥4 of 
subjects in one of the treatment groups)X X
Tier 3 Specific AEs, SOCs or PDLCsb(incidence <4 of 
subjects in all of the treatment groups)X
Change from BaselinecResults (Labs, Vital Signs) X
aAdverse Experience references refer to both Clinical and Laboratory AEs.
bIncludes only those endpoints not pre -specified as Tier 1 or not already pre -specified as Tier -2 endpoints.
c    Baseline measurements are taken at Visit 1.
Abbreviations: CI = Confidence interval; SOC=System Organ Class; PDLC=Pre -Defined Limit of Change; X  = 
results will be provided.
Statistical Methods for Pharmacokinetic Analysis 8.6.[ADDRESS_986081] evaluable sugammadex concentrations 
will be included . 
Individual dose normalized (dn) AUC0 -infand dnCmax values for each of the sugammadex
treatments (4mg/kg, 2mg/kg) will be natural log-transformed and evaluated with a linear 
fixed effect model having fixed terms for treatment and mode (IBW , ABW ) and an 
interaction term for mode x treatment. Kenward and Roger's method will be used to calculate 
the denominator degrees of freedom for the fixed effects.  Both interaction term (mode x 
treatment) and mode will be tested for statistical significance at alpha=0.05 for each of the 
pharmacokinetic parameters.  If either one or both of these terms for any or both of the
pharmacokinetic parameters (dnAUC0 -inf and dnCmax ) are statistically  significant ,then 
appropriate contrasts will be used to construct 90% confidence intervals (CIs) for the 
difference in least -squares (L S) means o n the log scale for dnAUC0 -inf and dnCmax for each 
of the modes of administration. These CI s will then be exponentiated to obtain a 90% CIs for 
the true dnAUC0 -infgeometric mean ratio, GMR (4mg/kg versus 2mg/kg) and true dnCmax 
GMR (4mg/kg versus 2mg/kg) for each of the modes of administration.  
  04YY9X 
  05C8LJ
Product:   MK-8616 72
Protocol/Amendment No.:   146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
ConfidentialIf both interaction (mode x treatment) and mode terms of the model for both dnAUC 0-  and 
dnCmax are not statistically  significant at alpha=0.05, then the data for both modes of 
administration will be pooled and the final model will include treatment as fixed effect. 
Ninety  percent (90%)CIs for the true dnAUC0 -inf GMR (4mg/kg versus 2mg/kg) and true 
dnCmax GMR (4mg/kg versus 2mg/kg) will be obtained from the model .  For each mode of 
administration LS means and corresponding 95% CI obtained from the model will also be 
reported for dnAUC0 -inf and dnCmax by  [CONTACT_3148]. 
Additionally , individual CL and Vd will be natural log-transformed and analy zed separately
using linear effects model as previousl y described. For each mode of administration, LS 
means and corresponding 95% CI sfor CL and Vd will be provided for each treatment .
For each mode of administration, individual values will be listed for each PK parameter 
(AUC0 -inf, AUC0 -last, Cmax, dnAUC0 -inf, dnCmax, CL, Vss, Vd, MRT, and t1/2) by 
[CONTACT_722002] (non -model -based) descriptive statistics will be provided: N 
(number of subjects with non-missing data), arithmetic mean, standard deviation, arithmetic  
percent CV (calculated as [ADDRESS_986082] deviation/arithmetic mean), median, minimum, 
maximum, geometric mean, and geometric percent CV (calculated as 100 x sqrt( exp(s2) -1), 
where s2 is the observed variance on the natural log -scale).
Mean (standard error ) and median (interquartile range ) concentration -time plots for each 
treatment and mode of administration will be provided.  Additionally  for each mode of 
administration, individual ratios overlaid with GMR and corresponding 90% CI for each 
treatment for dnAUC0 -infand dnCmax will be provided. Plots of dnAUC0 -inf versus ABW , 
dnAUC0 -inf versus IBW, dnCmax versus ABW ABW , dnCmax versus IBW will also be 
provide d.  
Summaries of Baseline Characteristics, Demographics, and Other Analyses 8.6.4
Demographic and Baseline Characteristics [IP_ADDRESS]
The comparability  of the treatment groups for each relevant characteristic will be assessed by 
[CONTACT_113827]/or graphs.  No statistical hypothesi s tests will be performed on these 
characteristics.  The number and percentage of subjects screened, randomized, the primary 
reasons for screening failure, and the primary  reason for discontinuation will be display ed.  
Demographic variables (e.g., age, gender, BMI, race, ethnicit y), baseline characteristics, 
surgical procedures, primar y and secondary  diagnoses ,and prior and concomitant therapi[INVESTIGATOR_721947] b y descriptive statistics or categorical tables.
Population PK Analyses [IP_ADDRESS]
Population -based methods of analysis may be explored at the completion of the study  to 
further characterize the PK profiles within morbidly  obese subjects and/or permit 
comparisons to historical data.   
  04YY9X 
  05C8LJ
Product:   MK-8616 73
Protocol/Amendment No.:   146-[ADDRESS_986083] and an interim statistician separate from the sugammadex
development team, both of whom will be unblinded during the IA, will perform the IA. Only  
the available data from the subjects (approximately  64 subjects total treated with 
sugammadex [~16 per combination of dose (2mg/kg, 4mg/kg) and weight -based dosing 
([ABW, IBW)], Table 7) for whom evaluable sugammadex PK samples are available will be 
included in the IA. 
Table 7 Sample Size for I nterim Analy sis
Approximate Number of Subjects that will T rigger Interim A nalysis
2 mg/kg (ABW) 4 mg/kg (ABW) 2 mg/kg (IBW) 4 mg/kg (IBW)
16 16 16 16
The IAof the pharmacokinetic parameters will be performed as previously  described in 
section 8.6.3.  In addition to the model -based analy sis, the interim unblinded statistician will 
also provide descriptive statistics for the pharmacokinetic parameters as previously  specified 
in 8.6.3. No individual listings for the PK parameters will be provided from the IAfor 
decision making
The siDMC will review the results of the planned IA to make recommendations regarding the 
need to study  the 16 mg/kg sugammadex dose. The decision about a 16 mg/kg dose will be 
based upon the evaluation of the 90% confidence intervals of the geometric mean ratio for 
both the Area Under the Curve0 -inf (AUC0- inf) and Maximum Concentration (Cmax ) form 
the IBW and ABW data.
Multiplicity 8.8
In this study ,the primary  hypothesis is a single comparison of sugam madex dosed with 
ABW and IBW using one endpoint in the primary  hypothesis ;therefore ,no corrections of 
multiplicity  are required. Sample Size and Power Calculations .
Sample Size and Power 8.9
Sample Size and Power for Efficacy A nalyses 8.9.1
This study  will enroll approximately  200 subjects in total. If subjects are equally  enrolled in
each NMBA strata , there would be ~20 subjects ineach of the fivetreatment groups within 
NMBA . However, due to enrollment kinetics ,an effort will be made to enroll approximately  
30% of vecuronium -treated subjects. Therefore , ~12 subjects will be randomized to each of 
the 5 treatment groups in the vecuronium stratum. The primary  approach to the assessment 
of sample size isvia simul ation using the primary  efficacy  model to compare time to 
recovery  for sugammadex dosed to ABW versus IBW . Time –to-recovery data aresimulated 
using distributional assumptions derived from dose -ranging efficacy data within the 
sugammadex clinical program, assuming that dosing according to IBW would result in 
weight -based dosing approximately  half of that from dosing according to ABW for either 
depth of block. In addition, the general conclusion in phase [ADDRESS_986084]:   MK - 8616 74
Protocol/Amendment No.:   146-01 
MK-8616-146-01 Final Protocol 5-Jul- 2018
Confidentialadministered 1 mg/kg in moderate block and 2 mg/kg in deep block would have time to 
recovery  increased by [CONTACT_722003] y 1 minute comparing to 2 mg/kg and 4 mg/kg , respectivel y.
Based on that assumption, subjects in the ABW group have a median time-to-recovery  of 
~2.[ADDRESS_986085] deviation of ~1.3, while subjects in the IBW have median time 
to recovery  of ~3.[ADDRESS_986086] deviation of ~2.3. Figure 2illustrates data 
simulated from the above assumption. 
Figure 2Illustrative scenario of Time-to-Recovery  to TOF ratio of 0.[ADDRESS_986087], with an alpha level of 0.05 based on 1000 
simulated samples and a function of sample size per group expected to be included in the 
analysis, and is carried out using [SAS v9.3]. Simulated power levels for the primary  
comparison as a function of sample size are shown in Table 8.
Table 8 Simulated power levels for the primary  compari son and related subgroup analy ses
as a function of sample size
N/arm 15 30 40 50 60 70 80
Power 51% 81% 89% 95% 98% 99% >99%
 
  04YY9X 
  05C8LJ
Product:   MK-8616 75
Protocol/Amendment No.:   146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
ConfidentialAssuming the difference of median time-to-recovery  in ABW and IBW groups is one minute 
based on the simulated data, a sample size of N~ 80 per group (across both NMBA and depth 
of block) provides estimated power of >99% to detect a shift in time-to-recovery ,as well as 
sufficient subject exposure to characterize safety  and tolerability  profiles of the distinct 
dosing paradigms. Although this study  is well- powered for an efficacy  comparison of 
sugammadex ABW and IBW, the subgroup analy ses by  [CONTACT_722004], given the range of simulated power levels in Table [ADDRESS_986088] one event of any treatment emergent arrhythmia in this 
study  depends on the number of subjects treated and the underly ing percentage of subjects 
with an AEin the study population.  If no events are observed among the 20 subjects in a 
treatment group, an upper bound of 95 %CI for subjects with any treatment emergent 
arrhythmia is ~16.8% (1 in every  6 subjects) in a treatment group . If no events are observed 
in an arm with 12 subjects, an upper bound of the 95% CI  would change to ~ 26.5%.
The estimate of incidence and the upper bound of the 95% CIfor the underly ing percentage 
of subjects with any treatment emergent arrhythmia within a treatment group are provided in
Table 9.  These calculations are based on the exact binomial method proposed by [CONTACT_492890] (1934) [7].The 95% CI sare provided in Table [ADDRESS_986089] in this study is an estimation of the absolute incidence of 
AEs in the sugammadex arms .
Table 9 Estimate of Incidence of Treatment Emergent Sinus Brad ycardia/Tach ycardia and 
95% Upper Confidence Bound Based on Hypothetical Number of Subjects wit h Any 
Treatment Emergent Arrhy thmia Among 20 Subjects in a Treatment Group
Hypothetical Number of  Subjects
With Any Treatment Emergent 
Arrh ythmiaEstimate of 
Incidence95% Upper Confidence 
Bound†
1 5% 24.9%
2 10% 31.7%
3 15% 37.9%
4 20% 43.7%
5 25% 49.1%
† Based on the two-tailed exact confidence interval of a binomial proportion (Clopper and 
Pearson, 1934) [7]. 
  04YY9X 
  05C8LJ
Product:   MK-8616 76
Protocol/Amendment No.:   146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
ConfidentialTable 10 Differences in Incidence in Any Treatment Emergent Arrh ythmia between the 
Sugammadex and Neostigmine Groups Assuming Two -Sided 5% alpha level with 20 
Subjects in a Treatment Group 
Incidence of Adverse Event Risk Difference
Sugammadex 
(%)Neostigmine 
(%)Percentage 
Points95% CIa
5% 10% 5 (-26%, 15.2% )
10% 20% 10 (-33.7%, 13.7%
Incidences presented here are hypothetical and do not represent actual adverse experiences 
in either group.
a Based on an asymptotic method (Farrington and Manning (1990)) .
Precision Estimates for Pharmacokinetic Parameters (AUC0 -inf, Cmax) 8.9.3
The precision of the estimated ratios of geometric means (4 mg/kg versus 2 mg/kg) of 
pharmacokinetic parameters obtained from this study  can be assessed by  [CONTACT_544669] -
width of the 90% confidence intervals expected for the given sample size and assumed 
variability . The between -subject geometric coefficient of variatio n (GCV) for sugammadex
AUC0 -inf obtained from the population analy sis is approximately  23%. Assuming a sample 
size of [ADDRESS_986090] deviation of 
0.23 for AUC0 -inf on the natural log scale, then the half width of the 90% confidence 
intervals of GMRs for AUC0 -inf on the log scale will be 0.138 . The lower and upper 90% 
confidence limits for the true GMRs will be given by  [CONTACT_111963]/1.148 and OBS*1.148 for AUC0 -
inf, respectivel y, where OBS is the observed GMR. Thus, for example, if the observed GMR 
for AUC0 -inf was 1.00, then the 90% CIs for the GMR would be 0.[ADDRESS_986091] (with a nominal 95% CI) for the primar y 
endpoint will be estimated pooled across depth of block and NMBA within each category  of 
each subgroup.  The following a re classification variables: 
Age category  (18-64, 65-74, >74 y ears)
Sex (female, male)
Race ( white, other )
Ethnicity  (Hispanic or Lat ino, Not Hispanic or Latino)
Region (U nited States, Non -[LOCATION_002])
Subgroup analyses/summaries will only be performed for those classification variables with 
≥10% participants in each subgroup. 
  04YY9X 
  05C8LJ
Product:   MK-8616 77
Protocol/Amendment No.:   146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
ConfidentialCompliance (Medication Adherence) 8.11
Compliance with dosage (in mg/kg) will be assessed based on the actual dosage (mg) of 
study  medication administered and the reported body  weight, per dosing occasion. Any 
dosage that differs by [CONTACT_726] 10% from the planned dosage will be listed. No statistical 
tests will be performed with respect to treatment compliance.
Extent of Exposure 8.12
The extent of exposure to study  medication will be summarized in a table presenting per 
treatment group the number of subjects who were random ized and received the study 
medication (i.e. were treated). If information on actual dose of study  medication is available, 
summary  statistics will be provided on the actual dose of study  medication received (mg/kg).
9.0LABELING, PACKAGING, STORAGE AND RETURN OF CLINICAL 
SUPPLIES
Investigational Product 9.[ADDRESS_986092] Name & Potency Dosage Form Source/Additional Information
Sugammadex 100 mg/ml Injection Provided centrall y by [CONTACT_1034].
Neostigmine methylsulfate
0.5mg/mlInjection Provided centrall y by [CONTACT_1034].
Glycopyrrolate 0.2mg/ml Injection Provided centrall y by [CONTACT_1034].
Sugammadex, neostigmine, and glycopyrrolate will be supplied to OR staff in masked syringe sfor 
administration to study subjects . 
Packaging and Labeling Information 9.[ADDRESS_986093] (or delegate) as needed. 
  04YY9X 
  05C8LJ
Product:   MK-8616 78
Protocol/Amendment No.:   146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
ConfidentialClinical Supplies Disclosure 9.3
The emergency  unblinding call center will use the treatment/randomization schedule for the 
trial to unblind subjects and to unmask treatment identity .In the event that the emergency 
unblinding call center is not available for a given site in this trial, the central electronic 
treatment allocation/randomization system (IVRS/I WRS) should be used in order to unblind 
subjects and to unmask treatment/vaccine identity .  The Sponsor will not provide random 
code/disclosure envelopes or lists with the clinical supp lies.
Treatment identification information is to be unmasked ONLY if necessary  for the welfare of 
the subject.  Every  effort should be made not to unblind the subject unless necessary . 
In the event that unblinding has occurred, the circumstances around the unblinding (e.g., 
date, reason and person performing the unblinding ) must be documented promptly , and the 
Sponsor Clinical Director notified as soon as possible.  Only the principal investigator [INVESTIGATOR_75307]’s code should be unblinded.  Trial site personnel and 
Sponsor personnel directly  associated with the conduct of the trial should not be unblinded to 
treatment assignment .Subjects whose treatment assignment has been unblinded (by [CONTACT_1275], [COMPANY_006] subsidiary , or through the emergency  unblinding call center) must be 
discontinued from study  drug , but should continue to be monitored in the trial .
Storage and Handling Requirements 9.[ADDRESS_986094]/Destruction/ Returns and Reconciliation 9.[ADDRESS_986095]/destruction procedure is documented .
Standard Policies 9.[ADDRESS_986096] access to a central electronic treatment 
allocation/ randomization system (IVRS/I WRS system) to allocate subjects, to assign 
treatment to subjects and to manage the distribution of clinical supplies. Each person 
accessing the IVRS system must be assigned an individual unique PIN.  They must use only 
their assigned PIN to access the system, and they must not share their assigned PIN with 
anyone. 
  04YY9X 
  05C8LJ
Product:   MK-8616 79
Protocol/Amendment No.:   146-[ADDRESS_986097], ethics review committee (IRB/ERC) or similar 
or expert committee; affiliated institution and employ ees, only under an appropriate 
understanding of confidentiality  with such board or committee, affiliated institution and 
employ ees.  Data generated by [CONTACT_26384], 
except to the extent that it is included in a publi cation as provided in the Publications section 
of this protocol.
Confidentiality of Subject Records 10.1.2
By [CONTACT_12570], the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/ERC, or regulatory  authority  representatives may consult and/or copy trial documents in 
order to verify  worksheet/case report form data.  By [CONTACT_17317], the subject 
agrees to this process.  If trial documents will be photocopi[INVESTIGATOR_75311]/case report form informatio n, the subject will be identified by [CONTACT_19494]; 
full names/initials will be masked prior to transmission to the Sponsor.
By [CONTACT_12570], the investigator agrees to treat all subject data used and disclosed in 
connection with this trial in accordance with all applicable privacy laws, rules and 
regulations.
Confidentiality of Investigator Information 10.1.[ADDRESS_986098] to the investigator, and all subinvestigators and trial site personnel, 
may be used and disclosed for trial management purposes, as part of a regulatory  
submissions, and as required b y law.  This information may include:
1.name, address, telephone number and e -mail address;
2. hospi[INVESTIGATOR_26342];
3.curriculum vitae or other summary  of qualifications and credentials; and
4.other professional documentation.
Consistent with the purposes described above, this information may be transmitted to the 
Sponsor, and subsidiaries, affiliates and agents of the Sponsor, in your country  and other 
countries, including countries that do not have laws protecting such information.  
Additionally , the investigator’s name [CONTACT_26407] [CONTACT_75387].  By [CONTACT_12570], the investigator expressly  consents to these uses and 
disclosures. 
  04YY9X 
  05C8LJ
Product:   MK-8616 80
Protocol/Amendment No.:   146-[ADDRESS_986099] between investigators, the Sponsor 
may share an investigator’s name [CONTACT_3669] [CONTACT_26388].
Confidentiality of IRB/IEC Information 10.1.[ADDRESS_986100] the name [CONTACT_19525]/IEC that reviews and 
approves this trial.  The Sponsor is also required to document that each IRB/IEC meets 
regulatory  and ICH GCP requirements by [CONTACT_26389]/IEC members and to make these records availa ble for 
regulatory  agency  review upon request b y those agencies.
Compliance with Financial Disclosure Requirements 10.2
Financial Disclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure by [CONTACT_722005] (21 CFR Part 54).  It is the 
Sponsor's responsibility to determine, based on these regulations, whether a request for 
Financial Disclosure information is required.  It is the investigator's/subinvestigator's 
responsibility  to comply  with any  such requ est.  
The investigator/subinvestigator(s) agree, if requested by [CONTACT_19489] 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certificati on and disclosure statements.  
The investigator/subinvestigator(s) further agree to provide this information on a 
Certification/Disclosure Form, commonly  known as a financial disclosure form, provided by 
[CONTACT_1034] . The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the [LOCATION_002] for these purposes.  This may involve the 
transmission of information to countries that do not have laws protecting personal data.
Compliance with Law, Audit and Debar ment 10.[ADDRESS_986101] the trial in an efficient and 
diligent manner and in conformance with this protocol; generall y accepted standards of Good 
Clinical Practice (e.g., International Conference on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice: 
Consolidated Guideline and other generally  accepted standards of good clinical practice); and 
all applicable federal, state and local laws, rules and regula tions relating to the conduct of the 
clinical trial.
The Code of Conduct, a collection of goals and considerations that govern the ethical and 
scientific conduct of clinical investigations sponsored by  [CONTACT_44873], is provided in Section 12.[ADDRESS_986102] for Clinical Trials .
The investigator also agrees to allow monitoring, audits, IRB/ERC review and regulatory  
authority  inspection of trial- related documents and procedures and provide for direct access 
to all trial -related source data and documents.
The investigator agrees not to seek reimbursement from subjects, their insurance providers or 
from government programs for procedures included as part of the trial reimbursed to the 
investigator b y the Sponsor. 
  04YY9X 
  05C8LJ
Product:   MK - 8616 81
Protocol/Amendment No.:   146-01 
MK-8616-146-01 Final Protocol 5-Jul- 2018
ConfidentialThe investigator shall prepare and maintain complete and accurate trial documentation in 
compliance with Good Clinical Practice standards and applicable federal, state and local 
laws, rules and regulations; and, for each subject participating in the trial, provide all data, 
and, upon completion or termination of the clinical trial, submit any other reports to the 
Sponsor as required by  [CONTACT_75389].
Trial documentation will be promptly  and fully disclosed to the Sponsor by [CONTACT_26391], 
copy ing, review and audit at reasonable times by [CONTACT_75391].  The investigator agrees to promptly  take any  reasonable steps that are 
requested b y the Sponsor as a result of an audit to cure deficiencies in the trial documentation 
and worksheets/case report forms.
The investigator must maintain copi[INVESTIGATOR_721948] t he trial in compliance with all applicable legal and regulatory  requirements.  This 
documentation includes, but is not limited to, the protocol, worksheets/case report forms, 
advertising for subject participation, adverse event reports, subject source data, 
correspondence with regulatory  authorities and IRBs/ERCs, consent forms, investigator’s 
curricula vitae, monitor visit logs, laboratory  reference ranges, laboratory  certification or 
quality  control procedures and laboratory  director curriculum vitae.  By [CONTACT_12570], 
the investigator agrees that documentation shall be retained until at least [ADDRESS_986103] consult 
with and obtain written approval b y the Sponsor prior to destro ying trial and/or subject files.  
ICH Good Clinical Practice 
guidelines recommend that the investigator inform the subject’s 
primary  physician about the subject’s participation in the trial if the subject has a primary  
physician and if the subject agrees to the primary  physician being informed.
The investigator will promptly  inform the Sponsor of any regula tory authority  inspection 
conducted for this trial.
Persons debarred from conducting or working on clinical trials by [CONTACT_90090]’s trials.  The investigator 
will immediately  disclose in writing to the Sponsor if any person who is involved in 
conducting the trial is debarred or if any proceeding for debarment is pending or, to the best 
of the investigator’s knowledge, threatened.
In the event the Sponsor prematurel y terminates a particular trial site, the Sponsor will 
promptly  notify  that trial site’s I RB/IEC. 
  04YY9X 
  05C8LJ
Product:   MK-8616 82
Protocol/Amendment No.:   146-[ADDRESS_986104] designate an overall coordinating 
investigator [INVESTIGATOR_8178] a multi -center trial (including multinational).  When more than one trial site 
is open in an EU country, [COMPANY_006], as the Sponsor, will designate, per country , a national 
principal coordinator (Protocol CI), responsible for coordinating the work of the principal 
investigators at the different trial sites in that Member State, accor ding to national 
regulations.  For a single -center trial, the Protocol CI is the principal investigator.  In 
addition, the Sponsor must designate a principal or coordinating investigator [INVESTIGATOR_721949], to the best of his/her 
knowledge, the report accuratel y describes the conduct and results of the trial [Clinical Study  
Report (CSR) CI].  The Sponsor may consider one or more factors in the selection of the 
individual to serve as the Protocol CI and or CSR CI (e.g., availability  of the CI during the 
anticipated review process, thorough understanding of clinical trial methods, appropriate 
enrollment of subject cohort, timely  achievement of trial milestones).  The Protocol CI must 
be a participating trial investigator.
Compliance with Trial Registration and Results Posting Requirements 10.[ADDRESS_986105] (FDAAA) of 2007 
and the European Medicines Agency  (EMA) clinical trial Directive 2001/20/EC, the Spo nsor 
of the trial is solely  responsible for determining whether the trial and its results are subject to 
the requirements for submission to http://www.clinicaltrials.gov, 
www.clinicaltrialsregister.eu or other local registries.  [COMPANY_006], as Sponsor of this trial, will 
review this protocol and submit the information necessary  to fulfill these requirements. 
[COMPANY_006] entries are not limited to FDAAA or the EMA clinical trial directive mandated trials.  
Information posted will allow subjects to identify  potentiall y appropriate trials for their 
disease conditions and pursue participation by [CONTACT_3379] a central contact [CONTACT_26393].  
By [CONTACT_12570], the investigator acknowledge s that the statutory  obligations under 
FDAAA, the EMA clinical trials directive or other locall y mandated registries are that of the 
Sponsor and agrees not to submit any information about this trial or its results to those 
registries.
Quality Management Sy stem 10.[ADDRESS_986106] operating procedures (SOPs) to ensure that trials are conducte d and 
data are generated, documented, and reported in compliance with the protocol, accepted 
standards of Good Clinical Practice, and all applicable federal, state, and local laws, rules and 
regulations relating to the conduct of the clinical trial.
Data M anagement 10.[ADDRESS_986107] data.  By [CONTACT_12570], the investigator acknowledges that his/her 
electronic signature [CONTACT_75412] y binding equivalent of a written signature.  By [CONTACT_75393] g 
his/her electronic signature, the investigator confirms that all recorded data have been 
verified as accurate. 
  04YY9X 
  05C8LJ
Product:   MK-8616 83
Protocol/Amendment No.:   146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
ConfidentialDetailed information regarding Data Management procedures for this protocol will be 
provided separatel y.
Publications 10.7
This trial is intended for publication, even if terminated prematurel y. Publication may include 
any or all of the following: posting of a synopsis online, abstract and/or presentation at a 
scientific conference, or publication of a full manuscript.  The Sponsor will work with the 
authors to submit a manuscript describing trial results within [ADDRESS_986108]'s last visit for the 
primary  outcome, [ADDRESS_986109] 
marketing (dispensed, administered, delivered or promoted), whichever is later.
These timelines may be extended for products that are not yet marketed, if additional time is 
needed for analysis, to protect intellectual property , or to compl y with confidentiality 
agreements with other parties.  Authors of the primary  results manuscript will be provided 
the complete results from the Clinical Study  Report, subject to the con fidentiality  agreement. 
When a manuscript is submitted to a biomedical journal, the Sponsor's policy  is to also 
include the protocol and statistical analy sis plan to facilitate the peer and editorial review of 
the manuscript.  If the manuscript is subseque ntly accepted for publication, the Sponsor will 
allow the journal, if it so desires, to post on its website the key sections of the protocol that 
are relevant to evaluating the trial, specifically  those sections describing the trial objectives 
and hypothes es, the subject inclusion and exclusion criteria, the trial design and procedures, 
the efficacy  and safet y measures, the statistical analy sis plan, and any  amendments relating to 
those sections.  The Sponsor reserves the right to redact proprietary informa tion.
For multicenter trials, subsequent to the multicenter publication (or after public disclosure of 
the results online at www.clinicaltrials.gov if a multicenter manuscript is not planned), an 
investigator and his/her colleagues may publish their data independentl y.  In most cases, 
publication of individual trial site data does not add value to complete multicenter results, 
due to statistical concerns.  In rare cases, publication of single trial site data prior to the main 
paper may be of value.  Limitat ions of single trial site observations in a multicenter trial 
should alway s be described in such a manuscript.
Authorship credit should be based on 1) substantial contributions to conception and design, 
or acquisition of data, or analysis and interpretatio n of data; 2) drafting the article or revising 
it critically  for important intellectual content; and 3) final approval of the version to be 
published. Authors must meet conditions 1, [ADDRESS_986110] also been made to all three of the preceding authorship criteria.  Although 
publication planning may  begin before conducting the trial, final decisions on authorship and 
the order of authors’ names will be made based on participation and actual contributions to  
  04YY9X 
  05C8LJ
Product:   MK - 8616 84
Protocol/Amendment No.:   146-[ADDRESS_986111] author is responsible for defending the 
integrit y of the data, method(s) of data anal ysis and the scientific content of the manuscript.
The Sponsor must have the opportunity  to review all proposed abstracts, manuscripts or 
presentations regarding this trial 45days prior to submission for publication/presentation. 
Any information identified by [CONTACT_26395]; this confidentiality  does not include efficacy  and safety  results. Sponsor review 
can be expedited to meet publication timelines.
11.[ADDRESS_986112] OF REFERENCES
[1] Kammerer MR, Porter MM, Beekley  AC, Tichansky  DS. Ideal Body Weight 
Calculation in the Bariatric Surgical Population. J Gastrointest Surg. [ADDRESS_986113];19(10):1758 -
62.
[2] Ingrande J, Lemmens HJ. Dose adjustment of anaesthetics in the morbidly obese. 
Br J Anaesth. 2010 Dec;[ADDRESS_986114] 1:i16-23.
[3] Eriksson LI, Sato M, Severin ghaus JW. Effect of a vecuronium -induced partial 
neuromuscular block on hypoxic ventilatory  response. Anesthesiology 
1993;78(4):693 -9.
[4] Eriksson LI. The effects of residual neuromuscular blockade and volatile 
anesthetics on the control of ventilation. Anesth Analg 1999;89:243 -51.
[5] Sampson HA, Munoz- Furlong A, Campbell RL, Adkinson J, Bock SA, Branum A, 
et al. Second symposium on the definition and management of anaphy laxis: 
Summary  report: Second National Institute of Allergy  and Infectious 
Disease/ Food Allergy  and Anaphy laxis Network symposium. J Allergy Clin 
Immunol 2006;117(2):391-7.
[6] American Societ y of Anesthesiologists. ASA physical status classification system 
[Internet]. Schaumburg, IL: ASA; 2017. Available from. 
https://www.asahq.org/res ources/clinical -information/asa -physical-status-
classification -system.
[7] Clopper CJ, Pearson ES. The use of confidence or Fiducial limits illustrated in the 
case of the binomial. Biometrika 1934;26(4):404-13.
[8] Miettinen O, Nurminen M. Comparative analy sis of two rates. Stat Med 
1985;4:213-26. 
  04YY9X 
  05C8LJ
Product:   MK-8616 85
Protocol/Amendment No.:   146-[ADDRESS_986115] for Clinical Trials 12.1
[COMPANY_006] *
Code of Conduct for Clinical Trials
I. Introduction
A. Purpose
[COMPANY_006], through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing and reporting these trials in 
compliance with the highest ethical and scientific standards. Protection of subject safety is the overriding concern in 
the design of clinical trials. In all cases, [COMPANY_006] clinical trials will be conducted in compliance with local and/or 
national regulations and in accordance with the ethical principles that have their origin in the Declaration of Helsinki. 
B. Scope
Such standards shall be endorsed for all clinical interventional investigations sponsored by [CONTACT_75395] (parties) employed for their execution (e. g., contract research organizations, collaborative research efforts). This 
Code is not intended to apply to trials which are observational in nature, or which are retrospective. Further, this Code 
does not apply to investigator -initiated trials which are n ot under the control of [COMPANY_006].
II.Scientific Issues
A. Trial Conduct
1.Trial Design
Except for pi[INVESTIGATOR_19354], clinical trial protocols will be hypothesis -driven to assess safety, efficacy 
and/or pharmacokinetic or pharmacodynamic indices of [COMPANY_006] or comparator products.  Alternatively, [COMPANY_006] may 
conduct outcomes research trials, trials to assess or validate various endpoint measures, or trials to determine 
subject preferences, etc.  
The design (i.e., subject population, duration, statistical power) must be adequate to address the specific purpose 
of the trial.  Research subjects must meet protocol entry criteria to be enrolled in the trial. 
2.Site Selection
[COMPANY_006] selects investigative sites based on medical expert[INVESTIGATOR_18700], access to appropriate subjects, adequacy of facilities 
and staff, previous performance in [COMPANY_006] trials, as well as budgetary considerations.  Prior to trial initiation, sites 
are evaluated by [CONTACT_75396].
3.Site Monit oring/Scientific Integrity
Trial sites are monitored to assess compliance with the trial protocol and general principles of Good Clinical 
Practice.  [COMPANY_006] reviews clinical data for accuracy, completeness and c onsistency. Data are verified versus source 
documentation according to standard operating procedures.  Per [COMPANY_006] policies and procedures, if fraud, 
misconduct or serious GCP -non-Compliance are suspected, the issues are promptly investigated. When necessary, 
the clinical site will be closed, the respons ible regulatory authorities and ethics review committees notified and 
data disclosed accordingly. 
B. Publication and Authorship
To the extent scientifically appropriate, [COMPANY_006] seeks to publish the results of trials it conducts.  Some early phase or 
pi[INVESTIGATOR_26346] -generating rather than hypothesis testing.  In such cases, publication of 
results may not be appropriate since the trial may be underpowered and the analyses complicated by [CONTACT_75397].
[COMPANY_006]’s policy on authorship is consistent with the requirements outlined in the ICH-Good Clinical Practice 
guidelines. In summary, authorship should reflect significant contribution to the design and conduct of the trial, 
performance or interpretation of the analys is, and/or writing of the manuscript.  All named authors must be able to 
defend the trial results and conclusions.  [COMPANY_006] funding of a trial will be acknowledged in publications.  
  04YY9X 
  05C8LJ
Product:   MK - 8616 86
Protocol/Amendment No.:   146-[ADDRESS_986116] Protection
A.IRB/ERC review
All clinical trials will be reviewed and approved by [CONTACT_75398]/ERC before being initiated at each site.  
Significant changes or revisions to the protocol will be approved by [CONTACT_1201]/ERC prior to implementation, except that 
changes required urgentl y to protect subject safety and well-being may be enacted in anticipation of IRB/ERC 
approval. For each site, the IRB/ERC and [COMPANY_006] will approve the subject informed consent form. 
B.Safety
The guiding principle in decision -making in clinical trials is that subject welfare is of primary importance.  Potential 
subjects will be informed of the risks and benefits of, as well as alternatives to, trial participation. At a minimum, trial 
designs will take into account the local standard of care.  Subjects are ne ver denied access to appropriate medical care 
based on participation in a [COMPANY_006] clinical trial. 
All participation in [COMPANY_006] clinical trials is voluntary.  Subjects are enrolled only after providing informed consent for 
participation.  Subjects may withdraw from a [COMPANY_006] trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
C.Confidentiality
[COMPANY_006] is committed to safeguarding subject confidentiality, to the greatest extent possible. Unless required by [CONTACT_2371], 
only the investigator, sponsor (or representative) and/or regulatory authorities will have access to confidential medical 
records that might identify the research subject by [CONTACT_2300].  
D.Genomic Research
Genomic Research will only beconducted in accordance with informed consent and/or as specifically authorized by 
[CONTACT_75399].
IV.Financial Considerations
A.Payments to Investigators
Clinical trials are time- and labor-intensive.  It is [COMPANY_006]’s policy to compensate investigat ors (or the sponsoring 
institution) in a fair manner for the work performed in support of [COMPANY_006] trials.   [COMPANY_006] does not pay incentives to 
enroll subjects in its trials.  However, when enrollment is particularly challenging, additional payments may be made
to compensate for the time spent in extra recruiting efforts.
[COMPANY_006] does not pay for subject referrals.  However, [COMPANY_006] may compensate referring physicians for time spent on 
chart review to identify potentially eligible subjects.
B.Clinical Research Fund ing 
Informed consent forms will disclose that the trial is sponsored by [CONTACT_44873], and that the investigator or sponsoring 
institution is being paid or provided a grant for performing the trial.  However, the local IRB/ERC may wish to alter 
the wording of thedisclosure statement to be consistent with financial practices at that institution.  As noted above, 
publications resulting from [COMPANY_006] trials will indicate [COMPANY_006] as a source of funding.
C.Funding for Travel and Other Requests
Funding of travel by [CONTACT_75400] (e.g.,to scientific meetings, investigator meetings, etc.) will be 
consistent with local guidelines and practices including, in the U.S., those established by [CONTACT_75401] (AMA). 
V. Investigator Commit ment
Investigators will be expected to review [COMPANY_006]’s Code of Conduct as an appendix to the trial protocol, and in signing 
the protocol, agree to support these ethical and scientific standards.
* In this document, "[COMPANY_006]" refers to [COMPANY_006] Sharp & Dohme Corp. andSchering Corporation, each of which is a 
subsidiary of [COMPANY_006] & Co., Inc.  [COMPANY_006] is known as MSD outside of the [LOCATION_002] and Canada.  As warranted by 
[CONTACT_74647], [COMPANY_006] also includes affiliates and subsidiaries of [COMPANY_006] & Co., Inc." 
  04YY9X 
  05C8LJ
Product:   MK-8616 87
Protocol/Amendment No.:   146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
ConfidentialCollection and Management of Specimens for Future Biomedical Research 12.2
1.Definitions
a.Biomarker:  A biological molecule found in blood, other body  fluids, or tissues that is a 
sign of a normal or abnormal process or of a condition or disease.  A biomarker may be 
used t o see how well the body  responds to a treatment for a disease or condition.1
b.Pharmacogenomics:  The investigation of variations of DNA and RNA characteristics as 
related to drug /vaccine response.2
c.Pharmacogenetics:  A subset of pharmacogenomics, pharmacogenetics is the influence of 
variations in DNA sequence on drug /vaccine response.2
d.DNA:  Deox yribonucleic acid.
e.RNA:  Ribonucleic acid.
2.Scope of Future Biomedical Research
The specimens consented and/or collected in this trial as outlined in Section 7.1.3. 4 –
Future Biomedical Research Sample swill be used in various experiments to understand:
oThe biology  of how drugs/vaccines work
oBiomarkers responsible for how a drug/vaccine enters and is removed b y the body
oOther pathway s drugs/vac cines may  interact with
oThe biology  of disease
The specimen(s) may be used for future assay  development and/or drug/vaccine 
development.
It is now well recognized that information obtained from study ing and testing clinical 
specimens offers unique opport unities to enhance our understanding of how individuals 
respond to drugs /vaccines , enhance our understanding of human disease and ultimately 
improve public health through development of novel treatments targeted to populations 
with the greatest need.  All specimens will be used by [CONTACT_75402] .
3.Summary of Procedures for Future Biomedical Research
a.Subjects for Enrollment
All subjects enrolled in the clinical trial will be considered for enrollment in the 
Future Biomedical Research sub -trial.
b.Informed Consent
Informed consent for specimens (i.e., DNA, RNA, protein, etc.) will be obtained 
during screening for protocol enrollment from all subjects or legal guardians, at a trial 
visit by [CONTACT_90094].  Informed consent for Future 
Biomed ical Research should be presented to the subjects on the visit designated in the 
trial flow chart .  If delayed, present consent at next possible Subject Visit.   Consent 
forms signed by [CONTACT_722006] e 
for regulatory  reasons.   
  04YY9X 
  05C8LJ
Product:   MK - 8616 88
Protocol/Amendment No.:   146-01 
MK-8616-146-01 Final Protocol 5-Jul- 2018
ConfidentialA template of each trial site’s approved informed consent will be stored in the 
Sponsor’s clinical document repository .
c.eCRF Documentation for Future Biomedical Research Specimens
Documentation of subject consent for Future Biomedical Research will be captured in 
the electronic Case Report Forms (eCRFs). Any specimens for which such an 
informed consent cannot be verified will be destroy ed.
d.Future Biomedical Research Specimen(s)
Collection of specimens for Future Biomedical Research will be performed as 
outlined in the trial flow chart. In general, if additional blood specimens are being 
collected for Future Biomedical Research, these will usually  be obtained at a time 
when the subject is having blood drawn for other trial purposes.
4. C onfidential Subject Information for Future Biomedical Research 
In order to optimize the research that can be conducted with Future Biomedical Research 
specimens, it is critical to link subject' clinical information with fu ture test results. In fact 
little or no research can be conducted without connecting the clinical trial data to the 
specimen. The clinical data allow specific analy ses to be conducted. Knowing subject 
characteristics like gender, age, medical history  and treatment outcomes are critical to 
understanding clinical context of analy tical results.
To maintain privacy  of information collected from specimens obtained for Future 
Biomedical Research, the Sponsor has developed secure policies and procedures. All 
speci mens will be single -coded per ICH E15 guidelines as described below . 
At the clinical trial site, unique codes will be placed on the Future Biomedical Research 
specimens.  This code is a random number which does not contain any personall y 
identify ing infor mation embedded within it. The link (or key) between subject identifiers 
and this unique code will be held at the trial site.  No personal identifiers will appear on 
the specimen tube.  
5.Biorepository Specimen Usage
Specimens obtained for the Sponsor will be used for analyses using good scientific 
practices.  Anal yses utilizing the Future Biomedical Research specimens may be 
performed by [CONTACT_1034] , or an additional third party (e.g., a university  investigator) 
designated by [CONTACT_1034] . The investigato r conducting the analy sis will follow the 
Sponsor’s privacy  and confidentiality  requirements. Any contracted third party  analyses 
will conform to the specific scope of anal ysis outlined in this sub- trial. Future Biomedical 
Research specimens remaining with the third party  after specific analy sis is performed 
will be reported to the Sponsor .
6. Withdrawal From Future Biomedical Research 
Subjects may withdraw their consent for Future Biomedical Research and ask that their 
biospecimens not be used for Future Biomedical Research.   Subjects may withdraw 
consent at any time by [CONTACT_59554] [INVESTIGATOR_75306]. If medical 
records for the main trial are still available, the investigator will contact [CONTACT_90095] ([EMAIL_1250]).  
  04YY9X 
  05C8LJ
Product:   MK - 8616 89
Protocol/Amendment No.:   146-[ADDRESS_986117]'s specimens will be flagged in the biorepository and restricted 
to main study  use only. If specimens were collected from study  participants specificall y 
for Future Biomedical Research, thes e specimens will be removed from the biorepository  
and destro yed. Documentation will be sent to the investigat or confirming withdrawal 
and/or destruction, if applicable. It is the responsibility  of the investigator to inform the 
subject of completion of the withdrawal and/or destruction, if applicable.  Any analyses 
in progress at the time of request for withdrawal/destruction or already  performed prior to 
the request being received by [CONTACT_75406]. No new analy ses would be generated after the request is 
received.
In the event that the medical records for the main trial are no longer available (e.g., if the 
investigator is no longer required by [CONTACT_722007]) or the specimens have been completel y anony mized, there will no longer be a 
link between the subject’s personal information and their specimens. In this situation, the 
request for withdrawal of consent and/or destruction cannot be proc essed.
7. Retention of Specimens 
Future Biomedical Research specimens will be stored in the biorepository  for potential 
analysis for up to [ADDRESS_986118] results are accessible only to the 
authorized Sponsor representatives and the designated trial administrator research 
personnel and/or collaborators. Database user authentication is highly secure, and is 
accomplished using network securit y policies and practices based on international 
standards to protect against unauthorized access.
9.
Reporting of Future Biomedical Research Data to Subjects
No information obtained from exploratory  laboratory  studies will be reported to the 
subject, family ,or physicians. Principle reasons not to inform or return results to the 
subject include: Lack of relevance to subject health, limitations of predictive capability , 
and concerns regarding misinterpretation.
If important research findings are discovered, the Sponsor may publish results, present 
results in national meetings, and make results accessible on a public website in order to 
rapi[INVESTIGATOR_90048].  Subjects will not be identified by  
  04YY9X 
  05C8LJ
Product:   MK - 8616 90
Protocol/Amendment No.:   146-[ADDRESS_986119] data 
privacy  concerns.  Data privacy  risks are largely  limited to rare situations involving 
possible breach of confid entiality .  In this highly unlikely  situation there is risk that the 
information, like all medical information, may  be misused.
12.Questions
Any questions related to the future biomedical research should be e
-mailed directl y to 
clinical.specimen.managemen [EMAIL_13829].
13.References
1.
National Cancer Institute: http://www.cancer.gov/dictionary /?searchTxt=biomarker
2.International Conference on Harmonization: DEFIN ITIO NS FOR GENOMIC 
BIOMARKERS, PHARMACOGENOMICS, PHARMACOGENETICS, GENOMIC 
DATA AND SAMPL E CODING CATEGORIES - E15; 
http://www.ich.org/ products/guidelines/efficacy /efficacy -single/article/definitions -
for-genomic -biomarkers- pharmacogenomics -pharmacogenetics- genomic -data-and-
sample -cod.html
3.Industry  Pharmacogenomics Working Group. Understanding the Intent, Scope and 
Public Health Benefits of Exploratory  Biomarker Research: A Guide for IRBs/IECs 
and Investigational Site Staff. Available at http://i -pwg.org/
4.Industry  Pharmacogenomics Working Group. Pharmacogenomics Informational 
Brochure for IRBs /IECs and Investigational Site Staff. Available at http://i -pwg.org/ 
  04YY9X 
  05C8LJ
Product:   MK-8616 91
Protocol/Amendment No.:   146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
ConfidentialApproximate Blood/Tissue Volumes Drawn/Collected by [CONTACT_75408] 12.3
Sample Types
Trial Visit :Screening
Visit 1Peri-anesthetic visi t
Visit 2Post anesthetic visit
Visit 3
Blood Param eter Approxim ate Blood Volume (mL)
Hem atology 2 2
Serum/Plasma Chemistry 5 5
Serum β-Hum an Chorionic 
Gonadotropin (β -hCG)a 3.5
PK for sugammadex 24-30 8-16
Blood (DNA) for Future 
Biomedical Research 8.5
Expected Total (mL) 3.[ADDRESS_986120]:   MK-8616 92
Protocol/Amendment No.:   146-[ADDRESS_986121]:   MK - 8616 93
Protocol/Amendment No.:   146-[ADDRESS_986122] (T 1),second (T 2), third (T 3), or fourth (T 4) twitch in response to 
TOF stimulation
T4/T1ratio TOF ratio: Ratio of the height of T 4over the height of T 1in the 
recording of the response to TOF stimulation. Ratio expressed in 
decimals (e.g., 0.7 or 0.8 or 0.9)
T1/[ADDRESS_986123]:   MK-8616 94
Protocol/Amendment No.:   146-01 
MK-8616 -146-01 Final Protocol 5-Jul-2018
Confidential13.0 SIGNATURES
Sponsor's Representative 13.[ADDRESS_986124] this clinical trial in accordance with the design outlined in this protocol 
and to abide by [CONTACT_19373] (including other manuals and documents 
referenced from this protocol).  I  agree to conduct the trial in accordance with generally 
accepted standards of Good Clinical Practice.  I also agree to report all information or data in 
accordance with the protocol and, in particular, I agree to report any serious adverse events 
as defined in Section 7.0–TRIAL PROCEDURES (Assessing and Recording Adverse 
Events ).  I also agree to handle all clinical supplies provided by [CONTACT_722008].  I understand that information 
that identifies me will be used and disclosed as described in the protocol, and that such 
information may be transferred to countries that do not have laws protecting such 
information.  Since the information in this protocol and the referenced Investigator’s 
Brochure is confidential, I understand that its disclosure to any third parties, other than those 
involved in approval, supervision, or conduct of the trial is prohibited.  I will ensure that the 
necessary  precautions are taken to protect such information from loss, inadvertent disclosure 
or access b y third parties.
TYPED NAME
[CONTACT_26410] 
  04YY9X 
  05C8LJ